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9Introduction
Figure 1.   The hepatitis B virus replication cycle
(Ganem et al. N Engl J Med 2004)
The hepatitis B virus: structure and morphology
The hepatitis B virus (HBV) belongs to the family of hepadna viridae and has a diameter of
42-47 nm1. The virus particle encloses a partially double-stranded DNA genome with a
length of approximately 3200 base pairs. Within the viral DNA genome 4 open reading
frames (ORFs) can be identified and are termed in analogy of their encoding proteins S
(surface), C (core), P (Polymerase), and X (HBx protein). The ORF S contains 3 regions, the
pre S1, pre S2 and S, which encode for the large, middle and small hepatitis B surface
glycoproteins depending on the start of the transcription site, respectively. The ORF C is
responsible for encoding the hepatitis B e antigen (HBeAg) and the core antigen (HBcAg).
After the binding of the virus particle to the hepatocyte, the HBV viral genome is converted
into covalently closed circular DNA (cccDNA) in the hepatocyte nucleus. The cccDNA
forms the key template for pregenomic RNA in the HBV replication cycle (Figure 1) and
acts as the reservoir for the HBV. In the hepatocyte cytoplasm, along with the core and
polymerase proteins the pregenomic RNA is assembled to virus particles. Sequentially, the
RNA is reversed transcribed into a HBV DNA minus strand, which is finally transcribed by
a HBV DNA polymerase into the HBV DNA plus strand. The formed particle can either be
excreted via the Golgi apparatus or recycled into the nucleus to form cccDNA2.
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Epidemiology
Worldwide, HBV infection is a common and important infection. Current estimates report
infection by HBV in about 2 billion people. Of these, approximately 400 million are chronically
infected by the HBV3.  Chronic infection (serum HBsAg-positivity > 6 months) is associated
with increased risk of developing liver cirrhosis and end-stage liver disease as decompensated
cirrhosis and hepatocellular carcinoma (HCC)4-6. HCC is the most frequent malignant
tumor of the liver and relates in 60-80% to chronic HBV7. It has been estimated that one
million people die as the result of chronic HBV infection each year.
The mode of HBV transmission is through parenteral contact of body fluids such as
transmission from mother to child during birth, sexual transmission, needle accidents or
intravenous drug use. In endemic areas (>8% incidence HBV infection) the disease is often
perinatally transmitted, whereas in areas with low incidence of HBV infection (<1%),
intravenous drug use, tattooing and sexual transmission are the main routes of transmission8.
Depending the age at time of exposure to HBV the risk for developing chronic HBV varies.
During the first year of the newborn the chance for chronicity is approximately 90%, risk
decreases to 30% between 1-5 years to approximately 2% above 5 years and adults9.
HBV genotypes
As a result of variety in expression of the viral genome, the HBV is divided into 8 different
genotypes, A-H10, 11. The HBV genotypes are also characterized by different geographical
and demographical distribution. Genotype A is predominantly found in North-west Europe
and North America, whereas genotypes B and C are mostly seen in Asian countries. Genotype
D is most common in the Mediterranean area. Consequently, Caucasians harbour
predominantly genotype A and D, and Asians almost exclusively the genotypes B and C12, 13.
In the current studies evidence is building that HBV genotypes are becoming more important
in the treatment of CHB. Erhardt and colleagues found that patients harbouring genotype
A respond better to treatment with interferon than those with genotype D14. A study with
peginterferon in HBeAg-positive chronic hepatitis B (CHB) showed higher response rates
for genotypes A and B when compared to genotypes C and D, respectively15. Spontaneous
HBeAg seroconversion seems to occur earlier in the natural course of the disease in
patients harbouring genotype B than in genotype C which has also been associated with
poorer clinical outcome16, 17.
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Treatment of Chronic Hepatitis B
The available therapeutic options for the treatment of chronic HBV are divided into two
types of treatment. One group embraces the nucleoside or nucleotide analogues (NA's),
the other group the interferons.
To date, lamivudine, adefovir and entecavir are the approved NA's for the treatment of
chronic HBV. The NA's are capable of inhibiting the HBV polymerase and thereby the HBV
replication. Lamivudine was the first NA approved for the treatment of chronic hepatitis B.
It is a nucleoside analogue of deoxycytidine, the enantiomer of 2'-deoxy-3'-thicytidine. One
year of treatment with lamivudine leads to HBeAg seroconversion in 16-18% of patients.
Lamivudine significantly reduces HBV DNA levels, normalizes serum ALT levels and improves
liver histology18-20. Long-term therapy with lamivudine is well tolerated with a minimum of
side effects, but its efficacy is limited due to the emergence of therapy resistant strains20, 21.
The viral resistance to lamivudine is caused by a point mutation in the YMDD motif of the
HBV polymerase gene of the virus which significantly reduces the efficacy of lamivudine.
These lamivudine resistant strains are found in up to 70% after 4-years treatment. Cessation
of therapy is frequently accompanied by reoccurrence of HBV replication22, 23.
Adefovir dipivoxil, an analogue of adenosine monophosphate was the second NA approved
for the treatment of CHB. A large trial showed 12% HBeAg seroconversion, suppression of
HBV DNA levels < 400 copies/mL in 21%, and histologic improvement in 53% after 48
weeks of treatment with adefovir. Resistance to adefovir was found in 3% of patients after
48 weeks treatment24. Entecavir, which has recently been approved for the treatment of
CHB is a guanosine analogue and capable of stronger suppression of HBV DNA levels
compared to lamivudine25. A 48-week treatment course with entecavir showed HBeAg
seroconversion in 21%, suppression of HBV DNA levels < 400 copies/mL in 67%, and
histologic improvement in 72% of patients. After 48 weeks no viral resistance to entecavir
was detected.
Interferons act by their capacity of suppressing cell proliferation, enhancing phagocytic
activity of macrophages, improved cytotoxicity of lymphocytes against target cells and
inhibiting the viral replication26, 27. A meta-analysis of 498 patients showed that 3-6 months
of IFN induced HBeAg loss in 33%, undetectable HBV DNA levels (by hybridization asssy)
in 37% and HBsAg loss in 8% of patients. Loss of HBsAg is closely related to improved long-
term histological and virological outcome as well as decreased risk of hepatic decompensation
and hepatocellular carcinoma7, 16, 28, and therefore regarded as the ultimate purpose of
therapy for chronic hepatitis B. In contrast to IFN, the treatment with NA does not lead to
enhanced HBsAg loss compared to spontaneous HBsAg seroconversion.
In the past few years, pegylated forms of IFN's have been introduced in the treatment of
CHB. Pegylation embraces the attachment of a polyethylene glycol (Peg) to the IFN molecule
which increases the half-life of the drug in the serum29. This allows dosing of peginterferon
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once a week instead of three times per week for conventional IFN. Pegylated interferons
have been reported to be more effective with a similar safety profile than conventional IFN
in patients with chronic hepatitis C30, 31. Recently, two large trials demonstrated that
peginterferon alfa-2a and peginterferon alfa-2b lead to HBeAg seroconversion in 32% and
29 % of HBeAg-positive CHB, respectively15, 32. Janssen et al. also demonstrated that higher
baseline ALT levels, lower baseline HBV DNA levels, and HBV genotype were positive
independent predictors for HBeAg seroconversion. The current available therapies are
effective in approximately one-third of HBeAg-positive CHB patients. In order to enhance
response rates combination therapy of immune stimulating combined with virus suppressive
medication have been investigated, but the addition of lamivudine to conventional IFN or
peginterferon did not lead to increased response rates compared to monotherapy with
IFN or peginterferon15, 32, 33. The optimal treatment for the growing population of difficult-
to-treat patients needs further investigation.
AIMS OF THE STUDY
To investigate the efficacy and adverse effects of peginterferon therapy alone
or combined with lamivudine in HBeAg-positive CHB
To investigate the efficacy of peginterferon therapy in previous non-responders to
conventional IFN and or lamivudine
To investigate the role of HBV genotype in response to peginterferon therapy
13Introduction
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ABSTRACT
Background: Treatment with interferon-alfa has been shown to be effective in one-third of
hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with
relevant adverse events.
Aim: To investigate the safety of peginterferon alfa-2b in 300 hepatitis B e antigen-positive
patients with compensated liver disease.
Methods: Patients were treated with peginterferon alfa-2b for 52 weeks combined with
either lamivudine 100 mg/day or placebo. Peginterferon alfa-2b was administered for 100
µg once a week for 32 weeks; thereafter, the dose was reduced to 50 µg once a week.
Adverse events and their effect on study medication were reported at monthly visits in a
standardized way.
Results: The most frequently reported side-effects were flu-like syndrome (68%), headache
(40%), fatigue (39%), myalgia (29%) and local reaction at the injection site (29%). These
symptoms typically occurred within the first month of therapy and subsided during the
course of therapy. Neutropenia and thrombocytopenia induced by peginterferon alfa-2b
increased the risk of infections and bleeding complications, but these complications were
rare and mild.The frequency of all side-effects was not different between patients treated
with peginterferon alfa-2b combined with lamivudine or placebo. In 69 (22%) patients the
dose of peginterferon alfa-2b was reduced prematurely. Of these dose reductions, 36 (52%)
were because of neutropenia. Therapy was discontinued in 28 (8%) patients. The most
frequent reasons for early discontinuation were psychiatric side effects (depression, psychosis)
and flu-like symptoms. Multivariate Cox regression analysis showed that low neutrophil
count at baseline and cirrhosis were independent predictors of dose reduction or therapy
discontinuation.
Conclusion: We conclude that in patients with chronic hepatitis B and compensated liver
disease prolonged peginterferon alfa-2b therapy is safe, and that pre-existent cirrhosis and
neutropenia are the most important predictors of dose reduction or early treatment
discontinuation.
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INTRODUCTION
An estimated 400 million people are chronically infected with hepatitis B virus (HBV).
Chronic hepatitis B (CHB) is the single most common cause of liver cirrhosis and
hepatocellular carcinoma (HCC) worldwide1. Interferon-alpha (IFN) is effective in about
one-third of the patients2. Reported HBeAg seroconversion rates range from 15 to 37%3–
5, depending on baseline characteristics such as alanine aminotransferase (ALT) levels and
viral load. Response to IFN therapy was shown to result in sustained clearance of hepatitis
B e antigen (HBeAg), HBV-DNA and normalization of aminotransferase levels6–8. Therapy
with IFN is associated with considerable side-effects. Most frequently reported side-effects
are flu-like syndrome, fatigue, headache and myalgia. Other clinically relevant side effects,
such as depression, anorexia and insomnia, occur less frequently. Cases of suicide attempts
during IFN therapy have been reported9–11. To improve response rates and possibly reduce
the number of side effects, newer forms of IFN have been developed. ‘Pegylated’ forms of
IFN (with a polyethylene glycolmoiety attached to it) have an improved pharmacokinetic
profile with a prolonged half-life time9. Pegylated interferons have been reported to be safe
and more effective than conventional IFN in patients with chronic hepatitis C12, 13.
Until now, the safety data of these pegylated forms of IFN in the treatment of CHB are
limited to the study of Cooksley et al.14, who investigated the safety of peginterferon alfa-2a
in CHB patients. In this study, we assessed the safety of peginterferon alfa-2b (Peg-IFN α-
2b) alone or in combination with lamivudine in HBeAg-positive CHB.
MATERIALS  AND METHODS
Patients
In a randomized multicentre trial reported previously15, 307 HBeAg-positive CHB patients
with compensated liver disease were treated with Peg-IFN α-2b in combination with either
lamivudine or placebo. Inclusion criteria were hepatitis B surface antigen (HBsAg)-positivity
for at least 6 months, age ³ 16 years, ALT at least twice the upper limit of normal (ULN) and
HBeAg positive on two occasions within 8 weeks prior to randomization. Patients were
excluded if they had been treated with antiviral medication in the previous 6 months or any
investigational drug within 30 days of entry in this protocol, were coinfected with hepatitis
C, hepatitis D or human immunodeficiency virus (HIV), had alcoholic hepatitis or other
causes of liver disease, had preexistent leucopenia or thrombocytopenia [white blood cell
count (WBC) ≤ 3000/mm3, neutrophils ≤ 1800/mm3, platelets ≤ 100 000/mm3], had
decompensated liver disease (prothombin time prolonged by > 3 seconds, serum albumin
< 35 g/L, ascites, encephalopathy, history of variceal bleeding) or had hypothroidism or
hyperthyroidism. Patients were also excluded in case of pregnancy, inadequate contraception,
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0 32                 52 78 weeks
Follow-up
Peg-IFN 100 Pg
Lamivudine
Peg-IFN 50 Pg
Follow-up
Peg-IFN 100 Pg
Placebo
Peg-IFN 50 Pg
The reported adverse events were also assessed in their relation to therapy by the treating
physician and reported as unrelated, possibly related, probably related or related to therapy.
Effect on study medication was scored as none, dose reduction or treatment discontinuation.
Serious adverse events (SAE) were defined as events resulting in death, events that are life-
threatening, require or prolong in-patient hospitalization, as well as events which result in
persistent or significant disability or incapacity, pregnancy, any congenital anomaly, cancer, or
drug overdose. Hepatitis flares were defined as an increase in serum ALT to at least three
times the baseline level. Psychiatric side effects included mood changes, irritability and
depression. Autoimmune phenomena are not reported because they were not systematically
investigated with, e.g. longitudinal assessment of auto-antibodies.
Figure 1. Treatment Schedule
any significant medical illness potentially interfering with the study or any contraindication
specified for IFN. Ethics committees of the participating centres approved of the protocol
and all patients provided written informed consent.
Study design
In this double-blinded trial, eligible patients were randomized to one of two treatment
regimens (Figure 1). All patients received Peg-IFN α-2b for 52 weeks. Patients were treated
with a 100 µg dose of Peg-IFN α-2b once a week until week 32, whereafter it was reduced
to 50 µg once a week. In addition, patients received either placebo or 100 mg lamivudine
orally. Patients were examined every 4 weeks during treatment and during the 6-month
post-treatment follow-up. At visits, routine physical examination was performed and blood
samples were obtained for haematological and biochemical screening [haemoglobin, WBC,
neutrophils, platelets, ALT and aspartate aminotransferase (AST)]. All adverse events were
reported by the treating physician on standard case-record forms and verified by the
trialcoordinating centre. All participating investigators were instructed, received a protocol
and were monitored every 3 months in order to ensure uniform scoring of side effects.
Adverse events were graded according to the WHO recommendations for grading of
acute and subacute toxicities16, and reported as mild, moderate, severe or life-threatening.
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Baseline characteristics
A total of 307 patients were randomized to treatment with Peg-IFN α-2b and either
lamivudine or placebo (ratio 1:1). The analysis of efficacy, that was reported previously, was
performed for 266 patients, and excluded patients who never started treatment (n=7),
were HBeAg-negative at the start of treatment (n=10), and patients from a single centre
where source data could not be verified (n=24)15. Because safety data were available and
could be verified for all patients, the 300 patients who received at least one dose of medication
were included in the present safety analysis. The baseline characteristics of these patients
are shown in Table 1. A total of 228 males (76%) and 72 females were treated with Peg-IFN
α-2b in combination with either lamivudine (n=148) or placebo (n=152). The mean age of
the patients was 35 years (range 16–72). The majority of patients (76%) were Caucasians.
For 230 patients, pre-treatment biopsies were available and of sufficient quality to be evaluated.
Of these patients, 26 (11%) had cirrhosis at liver biopsy. Among the 300 patients, 71 patients
(24%) had been treated with IFN, and 45 (16%) with lamivudine prior to entry in this study.
Guidelines on discontinuation of therapy in case of flares were provided to each investigator
before the start of the therapy. The decision to stop therapy in patients with flares and signs
of diminished liver function was left at the responsibility of the participating physician who
treated the patient.
Statistical analysis
Kaplan–Meier analysis was used to assess time until dose reduction or premature
discontinuation of therapy. For univariate analysis, the following factors were considered:
age, gender, race, mode of transmission, baseline levels of AST, ALT, bilirubin, neutrophils,
platelets and HBV-DNA, previous therapy with IFN or lamivudine and presence of cirrhosis.
To assess which variables independently predicted dose reduction or early discontinuation
of therapy, variables that were significant or approximated significance in the univariate
analysis (p < 0.2) were included in a multivariate analysis. Cox regression was used for
multivariate analysis. Chi-square analysis was carried out to compare frequencies of adverse
events. All statistical analyses were performed in SPSS version 10 (SPSS Inc, Chicago, IL,
USA).
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Table 1. Patient characteristics at baseline
Side effects
All treated patients reported one or more of the known side-effects of IFN. The frequency
of all side-effects was not significantly different between the Peg-IFN α-2b/placebo group
and the Peg-IFN α-2b/lamivudine group. Moreover, there was no difference in occurrence
of SAE and in the need for dose reduction or premature treatment discontinuation between
the treatment groups. Therefore, we combined the data of the two groups for all analyses.
The most frequently reported adverse events were flu-like syndrome (68%), headache
(40%), fatigue (39%), myalgia (29%) and local reaction at the injection site (29%) (Table 2).
IFN, interferon; ALT, alanine aminotransferase; HBV, hepatitis B virus;
ULN, upper limit of normal. * Mean ± s.d.
Characteristics   (n = 300) 
Age (yrs) 35 ± 13 
Gender, n (%) 
   Male 
   Female 
228 (76) 
72 (24) 
Weight (kg) * 73 ± 14 
Race, n (%) 
   Caucasian 
   Asian/ Other 
 
228 (76) 
72 (24) 
Mode of transmission, n (%) 
   Vertical 
   (Homo) sexual 
   Parenteral 
   Transfusion associated 
   Unknown 
66 (22) 
31 (10) 
27 (9) 
8 (3) 
173 (56) 
Previous IFN therapy, n (%) 71 (24) 
Previous lamivudine therapy, n (%) 45 (16) 
Histological diagnosis (%) 
   Cirrhosis 
   No cirrhosis 
 
26 (11) 
204 (89) 
ALT (x ULN)* 4.3 ± 3.5 
Platelets (109/L) 204 ± 60 
Neutrophils 3.4 ± 1.3 
Log HBV DNA* 9.0 ± 1.1 
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Figure 2. (A) Course of frequent adverse events during therapy and follow-up. (B)Adverse events:
Frequency of events in relation to peginterferon alfa-2b dose.
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These symptoms typically occurred within the first month of therapy and mostly subsided
during the course of therapy.  Alopecia and psychiatric symptoms (including depression
(n=26) and mood changes or irritability without depression (n=33)) occurred later in the
course of therapy (Figure 2). Transient visual impairment was recorded in five patients (2%),
but were not a reason for dose reduction or early treatment discontinuation. During
therapy, leucopenia (< 3.0 x109 U/L, grade II), neutropenia (< 1.5 x109 U/L, grade II) and
thrombocytopenia (< 75 x109 U/L, grade II) occurred in 42, 22 and 12% of the patients,
respectively (Table 2). All adverse events were reported less frequently after dose reduction
and were completely reversed after the end of therapy (Figure 2).
Hepatitis flares. A total of 71 hepatitis flares were reported, occurring during therapy in 31
patients and after the end of therapy in 40 patients. Flares occurred in 25% (37/148) of
patients in the Peg-IFN α-2b/lamivudine group and in 22% (34/152) of patients in the Peg-
IFN α-2b/placebo group (p = 0.5). The frequency of on- and posttreatment flares was not
different between groups. Two flares led to discontinuation of therapy. One patient had
signs of diminished liver function in the course of a flare. This patient had elevated bilirubin
levels (62 µmol/L), which resolved after normalization of ALT levels, but no other signs of
hepatic decompensation. None of the hepatitis flares resulted in sustained decompensated
liver disease or death.
* Includes depression, mood changes, irritability.
Table 2. Frequencies of adverse events
Adverse event Freq % 
Flu like Syndrome 68 
Headache 40 
Fatigue 39 
Myalgia 29 
Local reaction 29 
Alopecia 22 
Weight loss (> 10 %) 19 
Psychiatric* 20 
Abdominal pain 15 
  
Haematologic events  
Leucopenia (< 3.0 x 109 u/L) 42 
Neutropenia (< 1.5 x 109 u/L) 22 
Thrombocytopenia (< 75 x 109 u/L) 12 
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Serious adverse events. During the study, 33 SAE were reported. Of these 17 were judged as
probably related to therapy. Four patients had a serious hepatitis flare, and three developed
severe depression. Neutropenia (gradeIII or IV) was reported in three cases. Other SAE
that were probably related to therapy were syncope, seizures, psychosis, pancreatitis,
diarrhoea, anxiety and dizziness (resulting in a fall and a head wound). In 14 patients, the
serious adverse event led to early discontinuation of therapy [depression (n=4), flare (n=2),
neutropenia, seizures, pneumonia, psychosis, pancreatitis, severe diarrhoea, allergic reaction
with hypotension and pregnancy (all n=1)].
Bacterial infections and bleeding complications. Bacterial infections occurred in 12 patients
(4%). Nine of these 12 patients had neutropenia of at least grade II (< 1.5  x109/L) (Table 3).
The risk of infection increased with an increasing severity of neutropenia. Patients with
neutrophil counts below 1.5 x109/L had a significantly increased risk of infection compared
with patients with higher neutrophil counts (13.6% vs. 1.3%; p < 0.001). Infections included
urinary tract infection (n=4), gastroenteritis (n=2), tonsillitis (n=2), gingivitis (n=2), appendicitis
(n=1) and pneumonia (n=1). Overall, three severe bacterial infections were reported. In
two of these cases (pneumonia and appendicitis) the neutrophil count never dropped
below 1.5 x109/L. The third patient had a Salmonella gastroenteritis while his neutrophil
count was 0.7 x109/L. In four cases [pneumonia, appendicitis and gastroenteritis (n= 2)] the
infection necessitated hospital admission. All infections resolved without lasting complications.
The risk of bleeding complications was increased in patients with thrombocytopenia, especially
of grade III (< 50 x109/L) or IV. Reported bleeding complications in these patients were
epistaxis (n=2), gastrointestinal bleeding, subcutaneous bleeding and combined ecchymosis
plus epistaxis (Table 4a). Cirrhotic patients (n= 25) had a significantly higher risk of developing
thrombocytopenia than non-cirrhotic patients (54% vs. 8%, p < 0.001). Three of the cirrhotic
patients (with thrombocytopenia grade II and III) had bleeding complications (Table 4b).The
reported bleeding complications were not life-threatening and did not necessitate blood
transfusions.
Reported bacterial infections: urinary tract infection (n=4), gastroenteritis (n= 2), tonsillitis (n= 2),
gingivitis (n=2), pneumonia (n=1), appendicitis (n=1).
Table 3. Bacterial infections in patients with low neutrophil count
Neutrophils (x109 U/L) n Bacterial Infections (%) 
> 1.5  234 3 (1.3) 
1.0- 1.5 42 7 (16.6) 
0.5-1.0  15 1 (6.6) 
< 0.5  9 1(11.1) 
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Table 4. Bleeding complications according to level of thrombopenia
(A) and cirrhosis (B) in patients with low platelets
         Cirrhosis  (n = 26)         No Cirrhosis (n = 204) 
Platelets (U/L) n Bleeding complications   n (%) n 
Bleeding complications 
 n (%) 
> 75 x 109 12 0 (0) 188 4 (2) 
< 75 x 109 14 3 (21) 16 0 (0) 
 
Platelets (x 109 U/L) n Bleeding Complications (%) 
> 100 222 6(2.7) 
75-100 41 2 (4.9) 
50-75 28 1 (3.6) 
<  50 9 2(22.2) 
 
A
B
Dose reduction and discontinuation of therapy
In 69 patients (23%), the dose of Peg-IFN α-2b was reduced prematurely (Table 5). Of the
dose reductions, 37 (54%) occurred in the Peg-IFN α-2b/lamivudine group and 32 (47%) in
the Peg-IFN α-2b/placebo group. The dose of the blinded drug (lamivudine/placebo) was
not reduced in any of the patients. The main reasons for dose reduction were neutropenia
(52%), thrombocytopenia (10%), flu-like syndrome (10%) and combined haematological
abnormalities (8%). In four patients (6%), dose reduction was necessary because of psychiatric
symptoms and in seven patients because of flu-like-syndrome. Fifty percent of the dose
reductions occurred within the first 10 weeks. Thereafter, the number of dose reductions
decreased. Only two dose reductions were reported after week 32.
Peg-IFN α-2b therapy was discontinued prematurely in 28 patients (9%). In 24 patients, the
blinded drug (lamivudine/placebo) was also discontinued. In 10 patients, therapy
discontinuation was due to psychiatric side-effects. The second clinically important reason
for discontinuation was flu-like syndrome (n=3). Other reasons for early discontinuation
were acute pancreatitis, flare, decompensated liver disease and seizures (Table 5).
Discontinuation of therapy was reported more frequently before the scheduled dose
reduction of Peg-IFN α-2b at week 32. In univariate analysis, a low neutrophil count (< 3
x109/L) at baseline and presence of liver cirrhosis were associated with an increased risk of
dose reduction or discontinuation of therapy (Table 6). Cox regression analysis, including all
variables with a p-value < 0.2 in the univariate analysis, showed that both low neutrophil
count (hazard ratio 1.7, p = 0.03) and cirrhosis (hazard ratio 2.5, p = 0.001) remained the
only independent predictors of dose reduction or discontinuation of therapy.
Reported bleeding complications in patients with platelets < 100 x109 U/L: epistaxis n=2),
gastrointestinal bleeding (n=1), subcutaneous bleeding (n=1), ecchymosis and epistaxis (n=1).
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Table 5. Reasons for dose reduction and early discontinuation
DISCUSSION
The side-effects of conventional IFN therapy have been well documented in patients with
chronic hepatitis B and C8, 12, 14, 17, 18. The most common side effects include influenza-like
symptoms, fatigue, gastrointestinal symptoms (nausea, anorexia, weight loss), alopecia and
neuropsychiatric symptoms (irritability, depression, insomnia). IFN also causes mild bone
marrow depression with a temporary decrease in neutrophil, leucocyte and platelet counts.
These side effects have an impact on the quality of life, and can lead to dose reduction or
treatment discontinuation. This report is the first on safety of Peg-IFN α-2b in patients with
CHB. All patients reported one or more of the known adverse events of standard IFN. The
adverse events reported in our patients are largely those expected of standard IFN, and no
new events were reported. The frequency of the most common adverse events – flu-like
syndrome (66%), headache (39%), fatigue (37%) and myalgia (28%) – was comparable with
those previously reported in CHB patients treated with standard IFN in a dose of 4.5
MU14 or 10 MU t.i.w.17 for 16–32 weeks. Obviously, these comparisons with historical
controls must be interpreted with caution, as the treatment duration in our study was
longer and patient populations and therapy doses differ between studies.
Pegylated interferons have been reported to be safe and more effective in patients with
chronic hepatitis C8, 11, 12, 18, 19. In hepatitis C patients, the side-effect profile is the same as
that of standard IFN, with some difference in frequencies between different doses and
formulations. Haematological abnormalities (especially neutropenia) occur more frequently
Dose reduction n (%) Early discontinuation n (%) 
Neutropenia 36 (52) Psychiatric 10 (36) 
Thrombocytopenia 7 (10) Flu like syndrome 3 (11) 
Leucopenia 2 (3) Patient lost to follow-up 4 (14) 
Combined hematological 6 (8) Anemia 1 (4) 
Flu like syndrome 7 (10) Neutropenia 1 (4) 
Psychiatric 4 (6) Thrombocytopenia 1 (4) 
Fatigue 2 (3) Flare 1 (4) 
Local reaction 1 (1) Seizures 1 (4) 
Anorexia 1 (1) Acute pancreatitis 1 (4) 
Myalgia 1 (1) Decompensated liver disease 1 (4) 
Other 2 (3) Pneumonia 1 (4) 
  Other 3 (11) 
Total 69 Total 28 
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Table 6. Univariate analysis of association of baseline factors with dose modifications
(dose reduction or discontinuation of therapy)
Variable Risk of dose modifications (%) P-value 
Age 
  <35 
  ≥35 
 
27 
34 
0.19 
Sex 
  Male 
  Female 
 
29 
35 
0.27 
Weight 
  <75 kg 
   ≥75 kg 
 
34 
25 
0.11 
Race 
  Caucasian 
  Asian/ Other 
 
28 
37 
0.07 
ALT 
  < 4x ULN 
  ≥ 4x ULN 
 
29 
32 
0.47 
Log HBV DNA 
  < 9 
  ≥ 9 
 
36 
26 
0.06 
Bilirubin 
  < 11 
  ≥ 11 
 
28 
31 
0.57 
Platelets (x 109/L) 
 < 200 
 ≥ 200 
 
34 
25 
0.13 
Neutrophils  (x 109/L) 
 <3 
 ≥3 
 
39 
24 
0.003 
Cirrhosis 
  No 
  Yes 
 
29 
62 
0.0005 
Previous IFN therapy 
  Yes 
  No 
 
34 
28 
0.34 
Previous lamivudine therapy 
  Yes 
  No 
 
38 
27 
0.15 
 
in chronic hepatitis C patients treated with pegylated interferons (Peg-IFN α-2b or
peginterferon alfa-2a) than with standard IFN. The rate of dose reductions (22%) and
therapy discontinuations (9%) in our study is comparable with the frequencies reported
with pegylated interferons in patients with chronic hepatitis C8, 12, 13, 20 and with 24 weeks of
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peginterferon alfa-2a in patients with CHB14. The proportion of patients withdrawn from
therapy with pegylated interferons is similar to that of conventional IFN, but, when compared
with standard IFN, the proportion of patients requiring dose reductions is higher with Peg-
IFN α-2b in most hepatitis C studies8, 11, 12, 18. In CHB patients, the frequency of dose reduction
with peginterferon alfa-2a was higher than with conventional IFN (22–30% vs. 10%)14. The
increased rate of dose reductions with pegylated interferons seems mainly because of the
increased occurrence of neutropenia.
Until now it was unknown whether Peg-IFN α-2b-induced neutropenia and thrombo-
cytopenia indeed lead to an increase of bacterial infections and bleeding complications
respectively. In our study, neutropenia of < 1.5 x109/L significantly increased the risk of
bacterial infections (Table 5). However, the number of bacterial infections was rather low
and the infections were relatively mild. Only one serious infection (Salmonella gastroenteritis)
occurred in a patient with neutropenia above grade I. The risk of bleeding complications
was increased in patients with more severe thrombocytopenia, especially in patients with
pre-existent cirrhosis and platelets dropping below 75 x109 U/L. However, bleeding
complications were generally mild (epistaxis). Only one potentially life-threatening bleeding
complication (bleeding duodenal ulcer) occurred in a patient with mild liver fibrosis.
We also investigated the course of side-effects and adherence to therapy over time. Side
effects were most pronounced at the beginning of therapy and subsided over time. They
were generally well tolerated, but flu-like symptoms, lethargy and depression in some cases
necessitated dose reduction. Informing patients about the course of these adverse events
and adequate treatment with paracetamol and specific serotonin reuptake inhibitors (SSRIs)
may lead to an increased proportion of patients capable of completing the treatment.
Neutropenia and thrombocytopenia are other frequent causes for dose reduction.
Considering the mildness and rareness of complications of neutropenia in our patients, it
might be worthwhile to investigate, in a randomized study, if it is safe to accept grade III
neutropenia without dose reduction during Peg-IFN α-2b treatment for CHB. As, in our
study particularly, cirrhotic patients were at an increased risk of thrombocytopenia and
(minor) bleeding complications we recommend to monitor them closely and avoid a decrease
in platelet count below 75 x109/L. In a previous study in 217 cirrhotic patients with chronic
hepatitis C treated with peginterferon alfa-2a, despite substantial decreases in neutrophil
and platelet counts, episodes of infection and bleeding were mild and the treatment was
reported to be safe for this patient population21.
In conclusion, prolonged treatment with Peg-IFN α-2b in patients with CHB and compensated
liver disease is safe. Adding lamivudine to Peg-IFN α-2b did not affect Peg-IFN α-2b related
side effects. Haematological abnormalities during Peg-IFN α-2b treatment led to an increased
risk of minor infections and bleeding complications. Cirrhosis and low neutrophil count at
baseline are independent predictors of dose reduction or therapy discontinuation. In our
29The safety of Peginterferon
opinion, one should closely monitor patients with cirrhosis when initiating Peg-IFN α-2b
treatment.
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ABSTRACT
Background and aims: Flares are a well known phenomenon during antiviral treatment for
chronic hepatitis B. Little is known about the effect of flares on response. We investigated
the timing and characteristics of flares, in relation to treatment response (hepatitis B e
antigen loss).
Patients:  A total of 266 patients, participating in a global randomised controlled study, were
assigned to 52 weeks of 100 µg peginterferon α-2b weekly, combined with either daily
lamivudine 100 mg or placebo.
Results: Sixty seven patients (25%) exhibited 75 flares, with 38 (51%) flares in the combination
therapy and 37 (49%) in the monotherapy groups. Overall, 30% of patients with and 38% of
patients without a flare responded to therapy (p = 0.25). In 24 patients (36%) the flare was
followed by a decrease in hepatitis B virus (HBV) DNA (host induced flare). In 25 patients
(38%) the flare was preceded by an increase in HBV DNA (virus induced flare). In 17
patients (26%) the flare did not meet one of these criteria (indeterminate flare). Of patients
with host induced flare, 58% responded whereas only 20% of patients with virus induced
flares responded (p = 0.008). Hepatitis B surface antigen loss (n=8) was exclusively seen in
patients experiencing a host induced flare. Multivariate logistic analysis showed that host
induced flares was an independent predictor of response (p = 0.043).
Conclusion: Flares are not more common in responders than in non-responders to
peginterferon α-2b therapy. Virus induced flares, which occur after an increase in HBV
DNA level, and most probably are indicative for increased expression of viral antigens, did
not lead to treatment response. In contrast, host-induced flares which were followed by a
HBV DNA decrease were highly associated with treatment response.
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INTRODUCTION
Approximately 400 million people worldwide are chronically infected with the hepatitis B
virus (HBV). Chronic infection with HBV can lead to progression of liver diseases with
increased risk of cirrhosis, liver failure, and hepatocellular carcinoma1. Currently, interferon
á (IFN), lamivudine, and adefovir are the only registered drugs for treating chronic hepatitis
B (CHB). During treatment with IFN and after withdrawal of lamivudine therapy, flares of
inflammatory activity are a well-known phenomenon in CHB patients. Flares can be life
threatening but have also been associated with virological response. IFN induced flares
affect 25–40% of patients and have been attributed to the stimulatory effect of IFN, which
is capable of increasing T cell cytolytic activity and natural killer cell function2. Typically, these
flares are thought to occur in hepatitis B e antigen (HBeAg) positive patients during the
second to third month of therapy, and may precede HBeAg seroconversion2–5. In our previous
observation, flares during IFN were accompanied by an increased number of CD8+ specific
T lymphocytes6. Lamivudine related flares are seen during treatment but they do not occur
more often than in the natural course of CHB3. More important appear to be the flares
found after withdrawal of lamivudine, which occur in approximately 10–20% of patients3,7.
These flares are probably caused by reoccurrence of HBV replication, and have been
associated with decompensation of liver disease. To clarify the role of flares during and after
cessation of therapy, and to determine their relation with treatment response, we analysed
266 HBeAg-positive CHB patients who received pegylated (Peg)-IFN α-2b alone or in
combination with lamivudine.
PATIENTS  AND METHODS
Patients and study design
Data were extracted from a global multicentre randomised controlled trial comparing Peg-
IFN α-2b combined with either lamivudine or placebo in CHB8. Patients were assigned in a
1:1 ratio to receive 100 µg Peg-IFN α-2b weekly with 100 mg lamivudine daily (combination
therapy) or 100 mg Peg-IFN α-2b weekly with placebo (monotherapy). Duration of therapy
was 52 weeks. After 32 weeks, the dose of Peg-IFN α-2b was halved to 50 µg per week.
Post-treatment follow up lasted 26 weeks. Patients were eligible for treatment if they were
16 years of age or older, had been positive for hepatitis B surface antigen (HBsAg) for at
least six months, had been HBeAg positive on two occasions within eight weeks prior to
randomisation, and had two episodes of elevated serum alanine aminotransferase (ALT)
levels (at least twice the upper limit of normal (ULN)) on two occasions within eight weeks
prior to randomisation. Patients were excluded for the following reasons: treatment with
antiviral medication within six months or any investigational drug within 30 days of entry to
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the protocol, or presence of serum antibodies against hepatitis C virus, hepatitis D virus, or
human immunodeficiency virus. Other exclusion criteria were: alcoholic hepatitis or other
causes of liver disease; pre-existing leucopenia (white blood cell count ≤ 3000/mm3),
thrombocytopenia (platelets ≤ 100 000/mm3), or granulocytopenia (granulocyts ≤ 1800/
mm3); decompensated liver disease (prothombin time prolonged by > 3 seconds, serum
albumin <35 g/l, ascites, encephalopathy, history of variceal bleeding), or hypo- or
hyperthyroidism. Patients were also excluded in the event of any contraindication specified
for IFN. The ethics committee at the participating centres approved the protocol, and all
patients provided written informed consent.
Monitoring
All patients were seen monthly during therapy and follow up. At each visit, patients attended
the outpatient clinic for ALT measurement and other laboratory assessments.
Transaminases were assessed locally and expressed as xULN. In accordance with Honkoop
and colleagues7, a flare was defined as a threefold increase in serum ALT compared with
baseline levels. The time point of the flare was defined as the time of the peak level of serum
ALT. Multiple peak levels of thrice baseline serum ALT levels were considered as different
flares if they were separated by at least two measurements of ALT. In addition to ALT, HBV
DNA (detection limit 400 copies/mL, using inhouse Taqman PCR based on the Eurohep
standard9) was assessed at the same time points. Other virological parameters, such as
HBeAg (AxSYM; Abbott, Chicago, Illinois, USA) and HBsAg (AxSYM; Abbott) were assessed
at baseline, and at weeks 32, 52 (end of treatment), and 78 (end of follow up). HBV genotype
was assessed by Inno-Lipa assay (Innogenetics, Gent, Belgium). Response to therapy was
defined as serum HBeAg loss at the end of follow up.
Statistical analysis
The chi-square or Fisher’s exact test was used for categorical variables, and the Mann-
Whitney U test was performed for continuous data. In order to determine independent
predictors for the event flare, the baseline characteristics age, race, sex, mode of transmission,
pre-existing cirrhosis, ALT, log HBV DNA, HBV genotype, and previous IFN were included
in the univariate analysis. All tested variables with a p value < 0.15 were entered in the
multivariate time dependent Cox regression analysis. In order to determine independent
predictors for response within the flare population, we included the above mentioned
baseline variables plus timing of the flare, peak value of ALT during exacerbation, and flare
type (host induced versus virus induced) in a univariate and multivariate analysis. In the
event of multiple flares, the first flare was analysed for response to therapy. All data were
analysed using SPSS (version 10.1; SPSS Inc., Chicago, Illinois, USA). A p value of 0.05 was
considered significant (all two tailed).
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RESULTS
Flare versus non-flare
 Among the 266 patients analysed, 75 flares were recorded in 67 patients (25%). Six patients
experienced two flares and one patient three flares during treatment or follow up. Median
time point of flare was at week 60 (range 4-78), and median peak of ALT during flares was
12.3 xULN (range 2.3- 60.0). Of the 75 flares, 35 (47%) occurred during treatment and 40
(53%) after treatment discontinuation. In three patients, of whom two had pre-existing
cirrhosis, the flare was reported as a serious adverse event; in one patient this led to early
cessation of treatment. One patient had signs of diminished liver function (bilirubin 62
µmol/l) during the flare episode which resolved after normalisation of ALT values. During
the flare there were no other signs of hepatic decompensation. Characteristics of patients
with and without flare are given in Table 1.
Baseline Flare N = 67 
No Flare 
N = 199 P 
Age* 34±12 35±13 0.804 
ALT* (x ULN) 2.9±1.4 4.8±3.8 <0.001 
Log HBV DNA*  9.1±1.1 9.1±0.9 0.764 
Male (%) 52(78) 153(77) 0.947 
Transmission (%) 
- vertical 
- (homo)sexual 
- parenteral 
- transfusion 
- unknown 
 
18(27) 
7(10) 
8(12) 
4(6) 
30(45) 
 
42(21) 
22(11) 
21(11) 
3(2) 
111(56) 
0.132 
Genotype (%) 
- A 
- B 
- C 
- D 
 
19(28) 
7(10) 
11(16) 
26(39) 
 
71(36) 
16(8) 
28(14) 
77(39) 
0.738 
Race (%) 
- Caucasian 
- Asian 
 
47(70) 
13(19) 
 
149(75) 
39(20) 
0.432 
Cirrhosis (%) 10(19) 14(7) 0.060 
Previous lamivudine (%) 8(12) 31(16) 0.459 
Previous Interferon (%) 12(18) 47(24) 0.311 
Mono-therapy (%) 
Combination therapy (%) 
32(48) 
35(52) 
104(52) 
95(48) 
 
0.566 
 
Table 1. Characteristics at baseline of 266 patients with or without a flare of chronic hepatitis B
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Except for ALT and cirrhosis, all variables at baseline were comparable in the flare and non-
flare groups. Ten patients (19%) in the flare group and 14 patients (9%) in the non-flare
group had pre-existing cirrhosis (p = 0.06). Preexisting cirrhosis (p = 0.046; relative risk 2.0
(95% confidence interval (CI) 1.0-4.0)) and lower ALT at baseline (p = 0.0001; relative risk
1.4 (95% CI 1.2-1.6)) were also the only two  independent predictors for experiencing a
flare during therapy or follow up. Among the 75 flares, we recorded 37 (49%) in the
monotherapy group (35 patients) and 38 (51%) in the combination therapy group (32
patients). Baseline characteristics and response to therapy were not significantly different
between patients with a flare undergoing monotherapy or combination therapy (Table 2).
In five patients who exhibited a flare during or after treatment with a combination of Peg-
IFN α-2b and lamivudine, a YMDD mutant was detected. None of the flares was related to
emergence of a YMDD mutant.
 Peg-IFN α-2b 
Placebo 
N = 32 (48%) 
Peg-IFN α-2b 
Lamivudine 
N = 35 (52%) 
P- value 
Age* 36 ± 13.1 33 ± 10.8 0.44 
Male (%) 24 (75) 28 (80) 0.77 
Race (%) 
 Caucasian 
 Asian/Mongoloid 
 
21 (66) 
7 (22) 
 
26 (74) 
6 (17) 
0.73 
ALT* (x ULN) 2.9 ± 1.3 2.9 ± 1.5 0.94 
Log HBV DNA*  8.9 ± 1.3 9.2 ± 0.9 0.25 
Genotype (%) 
 A 
 B 
 C 
 D 
 
9 (28) 
2 (6) 
7 (22) 
11 (34) 
 
10 (29) 
5 (14) 
4 (11) 
15 (43) 
0.46 
Pre-existing Cirrhosis  (%) 5 (16) 5 (14) 0.99 
Dose reduction (%) 11 (34) 13 (37) 0.81 
Discontinuation of treatment (%) 4 (13) 5 (14) 0.83 
Flares during treatment (%) 20 (63) 14 (40) 0.067 
Time of flare † 36  (4-78) 60 (4-78) 0.27 
peak value flare* (x ULN) 13.7±6.9 16.4±13.8 0.89 
Response (%) 10 (31) 10 (29) 0.81 
 
Table 2. Characteristics of patients who had a flare, according to therapy
Table 1 and table 2: *Mean (SD). †Median (range).
Peg, pegylated; IFN, interferon; ALT, alanine aminotransferase; ULN, upper limit of normal; HBV,
hepatitis B virus.
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Flares in relation to response to treatment and genotype
Among the 67 flare patients, 20 (30%) responded to therapy, 10 (31%) in the monotherapy
and 10 (29%) in the combination group. Eight patients (12%) exhibited loss of HBsAg at the
end of follow up. On-treatment flares led more often to treatment response (41%) than
post-treatment flares (21%) (p = 0.081, Figure 1).
The frequency of flares was comparable for patients with different HBV genotypes (Figure
2A). However, the timing of flares and response to therapy differed among the HBV genotypes.
A total of 17 (74%) flares were recorded ontreatment in patients harbouring genotype A,
versus three (43%) in genotype B, four (33%) in genotype C, and eight (27%) in genotype D
(genotype A v other genotypes, p = 0.046) (Figure 2B). Treatment response in the flare
population was 47% for genotype A, 28% for B, 18% for C, and 19% for D (genotype A v
genotype D, p = 0.05) (Figure 2C). In addition to the timing of the flares and HBV genotype,
the magnitude of the ALT elevation was associated with treatment response. Mean ALT
during the flare within responders was 20.1 xULN versus 13.2 xULN in non-responders (p
= 0.036).
Host induced versus virus induced flares
Close online monitoring of serum ALT and HBV DNA levels revealed different patterns of
exacerbation (Figure 3). A flare was defined as ‘‘virus induced’’ when preceded by an increase
of least 1 log HBV DNA within four months. In general, these flares did not lead to a
decline in serum HBV DNA. A flare was defined as ‘‘host induced’’ when the preceding
HBV DNA levels were stable and when the flare was followed by a decline of 1 log HBV
DNA or more within the four months thereafter. Flares that did not meet one of these
criteria were classified as indeterminate. Only the first occurring flares were classified.
Figure 1. Proportion of response in relation to the time of the flare. Early presence of a flare
increased the chance of response (p = 0.081). Probability of response is shown on the y axis.
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For both host and virus induced flares, a minimum of 1 log HBV DNA alternation was
chosen to exclude random oscillation of serum HBV DNA as a basis for our flare criteria.
Twenty four flares (36%) were characterised as host induced, 25 (38%) were virus induced,
and 17 (26%) were indeterminate. One flare could not be classified due to missing HBV
DNA levels. Among the 67 flare patients, a host induced flare was strongly related to
response to therapy (Figure 4). Fourteen of the 24 patients (58%) with a host induced flare
responded to therapy compared with five of 25 patients (20%) with a virus induced and
one patient (6%) with an indeterminate flare. Moreover, eight patients (33%) with a host
induced flare, but none of those with a virus induced or indeterminate flare, were HBsAg
negative at the end of follow up. Seventy five percent of host induced flares versus 16% of
virus induced flares occurred during treatment (p < 0.0001). Median peak of ALT of host
induced flares was 13.8 xULN (range 5.3–60) and 12.1 xULN (range 3–45) for virus induced
flares. Eleven patients (61%) with a host induced flare during treatment and three (50%)
with a host induced flare after treatment responded to therapy. One patient (25%) with a
virus induced flare during treatment and four (19%) with a virus induced flare after treatment
responded to therapy. Within the flare population, multivariate analysis showed that the
occurrence of host induced flare (p = 0.043; relative risk 3.5; 95% CI 0.9–13.9) and the
Figure 2. (A) Frequency of flares according to hepatitis B virus (HBV) genotype. Among the most
important genotypes in our study (HBV genotypes A, B, C and D (n = 255)), no significant difference
in the frequency of flares was found. (B) Proportion of flares recorded during treatment among the
flare population according to HBV genotype (n= 63). On-treatment flares predominantly occurred
within genotype A. Genotype A versus genotype D, p = 0.029. (C) Flares leading to response according
to genotype (n=63). Genotype A versus genotype D, p = 0.050.
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magnitude of the ALT elevation (p = 0.031; RR 1.1; 95% CI 1.0–1.1) were the only factors
independently predictive of response (serum HBeAg loss). On-treatment flares were not
significantly related to response in this analysis (p = 0.65; RR 1.4; 95% CI 0.3–6.7).
After entering the occurrence of host induced flares in the previously described multivariate
analysis8 of the total study population (n=266), it remained a significant variable predicting
response (relative risk 2.4; 95% CI 1.0–5.8; p = 0.05).
Figure 3. (A) Case with host induced flare. The elevation in serum alanine aminotransferase
(ALT) was followed by a decrease in viral load (log hepatitis B virus (HBV) DNA). (B) Case with
virus induced flare. Serum ALT elevation was preceded by a sharp increase in serum HBV DNA.
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DISCUSSION
Spontaneous or treatment induced flares of inflammation are frequently observed in CHB.
These abrupt elevations in serum ALT are the result of an increase in intrahepatic
necroinflammation associated with expanded numbers of intrahepatic lymphocytes, in
particular cytotoxic T lymphocytes. Cytotoxic T lymphocytes are important to control
HBV but can also induce liver damage, depending on the environment and functional
capability10–15. Therapy with IFN is based on its stimulating effect on cytotoxic T lymphocyte
and natural killer cell function. Flares during standard IFN treatment occur typically during
the second and third month, and are thought to herald virological response and disease
remission2–5 16. Probably, these flares represent an attempt of the immune system to clear
the HBV infection.
In the current study, 29% of patients experienced a flare during therapy (n=34) or follow
up (n=33). We did not find a significant difference between the number of flares in patients
treated with Peg-IFN α-2b alone versus those treated with Peg-IFN α-2b in combination
with lamivudine. Patients with low baseline  ALT or pre-existing cirrhosis were more prone
to having flares. Cirrhotics tended to experience flares with high ALT values. These patients
should be monitored carefully during treatment with Peg-IFN α-2b, not only because of
their increased risk of flares but also because of their diminished residual liver function and
Figure 4. Host induced, indeterminate, and virus induced flares in relation to treatment response.
Host induced versus virus induced, p = 0.008.
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the consequent risk of developing decompensated liver disease. In the current study, no
permanent or life threatening signs of liver failure were encountered.
Overall, flares were not associated with response to therapy. However, flares during treatment
were more often associated with response than flares after treatment (Figure 1). In addition
to the timing of flares, response was dependent on HBV genotype and the magnitude of the
flare. Previously, a strong association between the severity of flares and HBsAg seroconversion
was found both in the natural history of CHB and in the setting of IFN therapy16 17. In these
studies, different definitions of flares were used. Nair and Perrillo16 defined a flare as an
increase in ALT of at least twice the ULN compared with baseline values while Yuen and
colleagues17 defined a flare as elevated transaminases above twice the ULN. As our patients
already had high baseline serum ALT levels (ALT levels above twice the ULN was used as an
entry criterion in this study population), these definitions were less suitable. For a clear
distinction between flares and relative mild elevations in serum ALT, we based our definition
on our previous experience, in which a threefold increase in serum ALT from baseline was
used7.
An important finding of the current study was the distinct patterns of flares occurring, with
stable viral load followed by a decrease in viral load (host induced flares) versus flares
preceded by an increase in viral load and variable viral loads afterwards (virus induced
flares). Patients with host induced flares responded significantly better to therapy than
those with a virus induced flare. Multivariate analysis revealed host induced flare as the only
independent factor predicting treatment response. Interestingly, all patients undergoing
HBsAg seroconversion had a host induced flare. This further supports the hypothesis that
full control and elimination of the virus, as indicated by clearance of HBeAg and HBsAg, is
achieved by a vigorous host immune response rather than by direct suppression of the
virus. Previous studies have shown that both spontaneous or IFN-α induced exacerbations
of hepatocellular necrosis in CHB are associated with induction of a virus specific CD4+ T
cell response18 19. Under IFN-α therapy such a hepatitis flare preceding sustained HBeAg
seroconversion requires a substantial increase in IL-12 production, along with induction of
the Th1 cytokines IFN-α and IL-220. Virus induced flares, which emerged after increasing
levels of HBV DNA, were related to treatment with the combination with lamivudine, and
more frequently seen after therapy. These flares were attributed to reactivation of HBV
after withdrawal of lamivudine. In general, they did not lead to disease remission but have
been associated with clinical exacerbation and disease progression7. In our study, virus
induced flares did not usually lead to response, and even appeared to be detrimental rather
than beneficial for treatment response.
Virus induced flares are not restricted to CHB patients treated with IFN and or lamivudine,
but also occur during the natural history of the disease. Liu et al described several patients
in whom significant flares were preceded by an increase in HBV DNA21.
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Studies in anti-HBe positive patients also showed episodes of flares as a result of sudden
reactivation of HBV22–24.
In general, flares during treatment with IFN or Peg-IFN α-2b should not be treated with
nucleoside analogues, and IFN should only be discontinued in case of impending liver failure.
Particular care should be taken in patients with cirrhosis who have the highest risk of
developing liver failure. On-treatment flares are likely to be host or IFN induced flares, and
could well herald loss of HBeAg or even HBsAg. In contrast, flares after treatment, especially
after lamivudine, are in general detrimental flares. These flares are typically seen after an
increase in HBV DNA and seldom lead to treatment response. Retreatment with a nucleoside
analogue should then be considered.
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ABSTRACT
Background and aims:  Hepatitis B surface antigen (HBsAg) loss is the hallmark of a complete
response to antiviral therapy for chronic hepatitis B. In this study, we investigated the
frequency of HBsAg loss after treatment with peginterferon α-2b.
Methods: In a multicenter randomized controlled trial, 266 HBeAg-positive patients were
treated for 52 wks with Peg-IFN α-2b (100 µg/wk) in combination with either lamivudine
(100 mg/day) or placebo. Post-treatment follow-up was 26 wks.
Results: At the end of follow-up, 95 (36%) of the 266 patients exhibited HBeAg loss, 18 (7%)
HBsAg loss, and 16 (6%) HBsAg seroconversion. Addition of lamivudine did not enhance
HBeAg loss, HBsAg loss, or development of anti-HBs. All 18 patients who showed HBsAg
loss had normal ALT; 11 (61%) of these patients were also hepatitis B virus (HBV) DNA
negative (< 400 copies/mL) at the end of follow-up. Loss of HBsAg differed according to
HBV genotype: 14% for genotype A, 9% for genotype B, 3% for genotype C, and 2% for
genotype D (A vs D: p = 0.006).
Conclusions: One year of Peg-IFN α-2b for HBeAg-positive patients led to HBsAg loss in
7%. Our study indicates that treatment with Peg-IFN α-2b is the best therapy to achieve
HBsAg clearance in patients with genotype A.
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INTRODUCTION
Worldwide, over 360 million people are chronically infected with hepatitis B virus (HBV)1.
Chronic HBV infection, defined as hepatitis B surface antigen (HBsAg) positivity for more
than 6 months, is associated with increased risk of developing cirrhosis, hepatic
decompensation, and hepatocellular carcinoma2, 3. Loss of HBsAg is closely related to improved
long-term histological and virological outcome as well as decreased risk of hepatic
decompensation and hepatocellular carcinoma4–7. Therefore, the ultimate purpose of therapy
for chronic hepatitis B is serum HBsAg negativity.
Treatment with nucleoside or nucleotide analogues is associated with reactivation of disease
activity after termination of treatment or, in case of continued therapy, development of
HBV variants which are resistant to treatment. Several studies with lamivudine have shown
absence or less than 2% loss of HBsAg 8–11. One-year treatment with adefovir dipivoxil
resulted in 1.6% loss of HBsAg, a percentage in the same range as spontaneous HBsAg
seroclearance12, 13. Treatment with standard interferon α  may lead to increased loss of
HBsAg 14, 15.  To date, little is known about loss of HBsAg due to treatment with pegylated
(peg)interferon α. Therefore, the aim of the studywas to investigate the incidence of and
the factors predicting HBsAg loss due to treatment with peginterferon α-2b alone or in
combination with lamivudine.
PATIENTS AND METHODS
This study was conducted as an ancillary study of a multicenter trial comparing combination
therapy of peginterferon α-2b and lamivudine versus peginterferon α-2b alone16. For this
study, 266 patients were analyzed after central evaluation of eligibility. Males and females
were included if they were 16 yr or older, had been positive for HBsAg and HBeAg for at
least 6 months prior to randomization, and had elevated serum ALT levels of at least twice
the upper limits of normal (ULN) 2 months before randomization. Exclusion criteria included
antiviral or immune modulatory treatment within 6 months; antibodies against hepatitis C,
hepatitis D, or human immunodeficiency virus; presence of decompensated liver disease
(prothrombin time prolonged by >3 s, serum albumin <35 g/L, ascites, encephalopathy,
history of variceal bleeding); pregnancy or recent drug or alcohol abuse. Other exclusion
criteria were: inadequate hematological levels, i.e., leucopenia (≤ 3,000/mm3),
thrombocytopenia (≤ 100,000/mm3), or granulocytopenia (≤ 1,800/mm3); serum α-
fetoprotein level of more than 50 ng/mL; hypo- or hyperthyroidism; radiological evidence of
hepatocellular carcinoma, or any contraindication specified for interferon.  All patients gave
written informed consent and the ethics committee at the participating centers approved
the protocol.
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Study Design
The patients received 100 µg/wk peginterferon α-2b for the first 32 wks, followed by 50
µg/wk peginterferon α-2b from week 32 to week 52. This was combined with either 100
mg lamivudine daily or a placebo. Post-treatment follow-up lasted 26 wks.
During therapy and follow-up, patients were seen monthly for routine examination as well
as biochemical and HBV DNA assessment. Transaminases were determined locally and are
therefore expressed as times the ULN. HBV DNA was assessed using in-house Taqman
PCR (detection limit 400 copies/mL) based on the Eurohep standard17. HBeAg (AxSYM,
Abbott, Abbot Park, IL, USA) and HBsAg (AxSYM, Abbott) status were measured at weeks
0, 32, 52 (during treatment) and week 78 (end of follow-up). HBV genotype (Inno-Lipa
Assay, Innogenetics) was assessed at baseline. HBeAg and HBsAg responses were defined
as loss of serum HBeAg and HBsAg at the end of follow-up, respectively. HBs- and HBe
seroconversion were defined as loss of HBs or HBe antigen, respectively, with development
of the corresponding antibodies. Liver histology was assessed at baseline and an optional
biopsy was performed at the end of treatment. Paired biopsies were available for 110
patients. Histological scoring was performed by one experienced pathologist according to
the histological activity index, modified by Ishak et al.18. The pathologist was blinded for
chronological order of biopsies and treatment schedule. Improvement of histology was
defined as a reduction of at least two points in the necroinflammatory score (range 0–18)
and one point in the fibrosis score (range 0–6).
Statistical Analysis
All datawere analyzed by means of SPSS version 10.1 (SPSS Inc., Chicago, IL). Chi-square or
Fisher’s exact test and the Mann-Whitney U test were used where appropriate (all 2-
tailed). A p value < 0.05 was considered significant.
RESULTS
Loss of HBeAg and HBsAg
At the end of follow-up, 95 (36%) of the 266 patients exhibited HBeAg loss, 18 (7%) loss of
HBsAg, and 16 (6%) HBsAg seroconversion. Among patients with HBeAg loss, 19% were
also HBsAg negative at the end of follow-up. Addition of lamivudine did not enhance HBeAg
loss, HBsAg loss, or development of anti-HBs. At the end of follow-up,HBeAg clearance
was found for 36% in the monotherapy and 35% of the combination group. HBsAg clearance
at the end of follow-up was 7% for both treatment groups. Results of HBeAg and HBsAg
testing were available for weeks 0, 32, 52, and 78. Percentages of HBeAg- and HBsAg
clearance and HBV DNA < 400 copies/mL at these time points are shown in Figure 1.
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Twelve patients became HBsAg negative before week 52 (end of treatment) and 6 became
HBsAg negative between week 52 and week 78 (end of follow-up). Baseline characteristics
for nonresponders and for those who showed loss of serum HBeAg and/or HBsAg are
given in Table 1. Compared to nonresponders, baseline HBV DNA values were lower
among those exhibiting HBeAg loss (p = 0.043), but not those with HBsAg loss. Compared
to nonresponders and HBeAg responders, patients with HBsAg loss were significantly
older (p = 0.001).
Figure 1. Course of serum HBeAg, HBsAg, and PCR-negativity (< 400 copies/mL) during treatment
and follow-up. Data for both Peginterferon/placebo and Peginterferon/lamivudine were combined.
Percentages were calculated for patients who were HBeAg or HBsAg responders at the end of
follow-up.
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Loss of HBeAg and HBsAg in Relation to HBV DNA, ALT, and Histology
Among HBeAg responders, 59 (65%) patients had normal serum ALT, 62 (69%) HBV DNA
<200,000 copies/mL, and 9 (22%) HBV DNA < 400 copies/mL by PCR at the end of follow-
up (Figure 2). No differences were found between the different treatment regimens and
HBV DNA response or ALT normalization. Among HBsAg responders, all patients had
normal serum ALT and HBV DNA < 200,000 copies/mL, and 11 (61%) had HBV DNA
<400 copies/mL by PCR at the end of follow-up. In the nonresponder group, we found 28
(18%) patients with normal serum ALT, 12 (9%) withHBV DNA < 200,000 copies/mL, and
none with HBV DNA < 400 copies/mL by PCR at the end of follow-up.
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As far as histology is concerned, improved (reduction of >2 points HAI) necroinflammation
scores were found for 36 (38%) of the HBeAg responders, 7 (39%) of the HBsAg responders,
and 39 (23%) of the nonresponders (HBeAg and HBsAg responders versus nonresponders,
p = 0.016). Among HBsAg-negative patients, the fibrosis score had improved in 2 cases and
worsened in 3 cases, while 3 patients showed no change (median 0, range -2–1). Fibrosis
scores were not significantly different among nonresponders, HBeAg responders, and HBsAg
responders.
Loss of HBeAg and HBsAg in relation to genotype
The most common HBV genotypes were genotype A (n=90), B (n=23), C (n=39), and D (n
=103) (Table 2). HBV genotypes A (97%) and D (95%) were found predominantly among
Caucasians; among Asians, genotypes B (78%) and C(80%)were the most common (Table
2). Patients with genotype A lived in Northwest and Eastern Europe, patients with genotype
B or C in all continents, and those with genotype D primarily in the Mediterranean countries
and Northwest Europe.
HBV genotype was not only associated with HBeAg response, but also with HBsAg response
(Figure 3). Loss of HBsAg was found predominantly in patients harboring genotype A.
Thirteen of the 90 genotype A patients (14%), 2 of the 23 genotype B (9%), 1 of the 39
genotype C (3%), and 2 of the 103 genotype D (2%) patients had lost HBsAg at the end of
follow-up (genotype A versus genotype D, p = 0.006). Anti-HBs was seen in 12 patients
with genotype A (13%), 2 with genotype B (9%), 0 with genotype C, and 2 with genotype D
(2%). Among HBeAg responders, 31% of genotype A, 20% of genotype B, 9% of genotype C,
and 8% of genotype D patients lost serum HBsAg as well; anti-HBs was seen in 29%, 20%,
0%, and 8% at the end of follow-up for genotypes A, B, C, and D, respectively.
Figure 2. HBV DNA response and
ALT normalization at the end of
follow-up in HBeAg-positive (n=
171), HBeAg-negative (n=95), and
HBsAg-negative (n=18) patients at
the end of follow-up. HBeAg-
positive versus HBeAg-negative
patients: for HBV DNA <200,000
copies/mL, p < 0.0001; HBV DNA
<400 copies/mL, p = ns; and ALT
normalization, p < 0.0001. HBeAg-
negative versus HBsAg-negative: for
HBV DNA <200,000 copies/mL, p
= 0.034; HBV DNA <400 copies/
mL, p < 0.0001; and ALT
normalization p = 0.002.
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 HBV Genotype 
Characteristics A N = 90 
B 
N = 23 
C 
N = 39 
D 
N = 103 
Age (yrs)† 43 ± 14.1 33 ± 8.1 35 ± 10.0 29 ± 10.0 
Weight (kgs) † 77 ± 12.8 64 ± 10.1 68 ± 11.8 74 ± 15.2 
ALT (x ULN) † 4.2 ± 2.6 4.2 ± 2.2 3.9 ± 2.8 4.6 ± 4.5 
Log HBV DNA† 9.1 ± 0.8 8.3 ± 1.4 8.3 ± 0.9 9.5 ± 0.9 
 
Histology* 
 Fibrosis 
 Necroinflammation 
 
 
3 (0-6) 
6 (2-10) 
 
3 (0-6) 
6 (3-8) 
 
3 (0-6) 
5 (2-10) 
 
2 (0-6) 
4 (1-10) 
 
Race (%) 
 Caucasian 
 Asian/Mongoloid 
 Other 
 
 
 
87 (97) 
1 (1) 
2 (2) 
 
 
1 (4) 
18 (78) 
4 (17) 
 
 
2 (5) 
31 (80) 
6 (15) 
 
 
98 (95) 
0 
5 (5) 
 
Area of enrollment (%) 
 North. & West. Europe 
 Eastern Europe 
 Mediterranean 
 East Asia 
 North America 
 
 
 
55 (61) 
28 (31) 
5 (6) 
0 
2 (2) 
 
 
7 (30) 
0 
0 
11 (48) 
5 (22) 
 
 
12 (31) 
0 
0 
17 (44) 
10 (26) 
 
 
24 (23) 
2 (2) 
77 (75) 
0 
0 
 
Table 2. Baseline characteristics and geographical distribution of patients with HBV Genotype A, B,
C, or D
†Mean ± SD. *Median (range).
DISCUSSION
The ultimate endpoint of antiviral therapy for chronic HBV infection is loss of HBsAg,which
is accompanied not only by disease remission in terms of ALT normalization, but also by a
significantly decreased risk of liver failure and hepatocellular carcinoma4–6. Spontaneous
HBsAg loss is uncommon and varies from 1% to 2% annually19.
In the current study,  after 52 wks of peginterferon α-2b therapy in combination with
lamivudine or placebo and 26 wks of follow-up, we found serum HBsAg loss in 18 patients
(7%) and development of anti-HBs in 16 patients (6%). Adding lamivudine did not enhance
HBeAg- or HBsAg seroclearance. Previous studies have shown that treatment with nucleoside
or nucleotide analogues, such as lamivudine and adefovir, probably do not lead to an enhanced
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Figure 3. Proportion of HBeAg- and HBsAg clearance at the end of follow-up according to genotype
(n = 266). *Genotype A versus D, p = 0.006.
rate of HBsAg seroclearance 8–11, 20, 21. Nevertheless, in several single cases, prolonged adefovir
therapy induced a sharp reduction of cccDNA and HBsAg seroconversion 22. Therefore,
the hypothesis that a decrease in intrahepatic viral load itself may be associated with
restoration of a noncytolytic Th1 response and HBsAg seroconversion deserves further
investigation23. A recent pilot study using tenofovir did show HBsAg seroconversion in 5 of
35 (14%) patients24. This needs to be confirmed in a large randomized study which was
initiated recently.
We previously demonstrated that HBeAg seroconversion after treatment with standard
interferon α persisted longer than after lamivudine therapy25. Furthermore, HBsAg
seroconversion occurred more frequently in patients treated with interferon α than those
receiving lamivudine. In keeping with the sustained response after interferon α therapy, a
prolonged follow-up study by van Zonneveld showed that over a median period of 8.8 yr,
the HBsAg seroconversion rate increased up to 52% in chronic hepatitis B patients who
responded to interferon therapy26. Overall, these results support the hypothesis that peg-
interferon α, more than nucleoside analogs, can induce a complete and vigorous immune
response which leads not only to loss of HBeAg, but also to loss of HBsAg.
Detailed analysis of our data showed that both HBeAg and HBsAg seroconversion were
strongly associated with the HBV genotype. Among responders harboring genotype A,
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there was an HBsAg seroclearance rate of 31%. Genotype A patients exhibited a high rate
of HBeAg and HBsAg loss, not only as a result of peginterferon α therapy but also
spontaneously27. This probably relates to the presence of genotype-dependent mutations
llocated within the basic core promotor region of the genome28. Among Asian patients, we
found a higher HBeAg- and HBsAg seroconversion rate for those with genotype B than for
those with genotype C.  This confirms the results of previous studies that showed better
results of interferon α for patients with genotype B, also due to a response predisposition
caused by core promotor mutations29–32. Although our results revealed a strong association
between HBV genotype and HBsAg loss, the absolute number with HBsAg clearance is
relatively low. Therefore, multivariate analysis for the prediction of HBsAg loss could not be
performed. Nevertheless, the clear association between HBV genotype and loss of HBsAg
should be taken into account in future studies.
Two global chronic hepatitis B studies on peginterferon α-2a, in a similar therapeutic regimen
as our study, have recently been finalized. In a difficult-to-treat HBeAg-negative population,
Marcellin et al. found4% HBsAg seroconversion33. This low HBsAg response can probably
be explained by the fact that HBeAg-negative patients often harbor the non-A genotype
and carry pre-core mutations which may hamper effective immune stimulation by interferon
α. In an HBeAg-positive population treated for 1 yr with peginterferon α-2a, Lau and
colleagues found 32% HBeAg seroconversion, 3% HBsAg loss, and 3% HBsAg
seroconversion21.  When this rate of HBsAg loss is compared with our results, it is important
to note that 87% of their population were Asian, for whom low HBsAg seroclearance rates
after interferon á have been described previously21. The HBsAg loss among our Asian patients
was 5%. An interesting finding of our study is the relatively large number of patients (39%)
for whom serum HBV DNA could still be detected by Taqman technology after HBsAg
seroclearance.  Yuen et al. recently described a Chinese chronic HBV population with HBsAg
seroclearance, spontaneously, or after interferon α therapy. Upon long-term follow-up,
they found serum HBV DNA in only 2%, but intrahepatic HBV DNA (mainly cccDNA) in
37% of the population4. This study and earlier studies showing a delay between postinterferon
α HBsAg seroclearance and HBV DNA negativity by PCR4, 34 suggest that with continued
follow-up, HBV DNA might further disappear from serum in most patients who become
HBsAg negative. This is further supported by analysis of our data from a previous study,
which showed that 90% of the HBsAg-negative patients also had undetectable HBV DNA
levels by PCR after prolonged follow-up26.
In conclusion, 7% of patients treated with peginterferon α-2b showed HBsAg loss, a response
higher than that reported for lamivudine and/or adefovir. HBV genotypes were associated
with HbeAg and HBsAg seroclearance. In particular, patients with genotype A seemed to
benefit from peginterferon α-2b therapy, with an HBsAg clearance rate of 14% overall and
31% among responders who had lost HBeAg.
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ABSTRACT
Objectives: Antiviral therapy leads to HBeAg seroconversion in 10-40% of the patients with
HBeAg-positive chronic hepatitis B. Non-response may result in progression of liver disease
and increased risk of hepatocellular carcinoma. As part of a global randomized controlled
trial we investigated the efficacy (i.e. loss of HBeAg at the end of follow-up) of peginterferon
alfa-2b (Peg-IFN α-2b) in patients who failed to respond to previous courses of standard
interferon (IFN) or lamivudine.
Methods: We analyzed a total of 76 previous non-responders, 37 were non-responders to
standard IFN, 17 were non-responders to lamivudine, and 22 were non-responders to
both therapies. All patients received a 52-week course of 100 µg Peg-IFN α-2b weekly
combined with either 100 mg lamivudine daily or a placebo. After therapy patients were
followed for 26 weeks.
Results: Thirteen (35%) non-responders to previous IFN, 5 (29%) non-responders to previous
lamivudine, and 4 (22%) non-responders to both IFN and lamivudine responded to treatment
with Peg-IFN α-2b. No difference in response was found for those treated with Peg-IFN
α-2b alone or in combination with lamivudine. Non-responders to prior IFN therapy with
baseline ALT > 4 x ULN responded better to Peg-IFN α-2b than those with ALT levels  ≤
4 x ULN (53% vs. 20%, respectively, p = 0.036).
Conclusions: Peg-IFN α-2b is effective in approximately one-third of patients who failed to
respond to previous treatment with standard IFN or lamivudine. High serum ALT level at
baseline of Peg-IFN α-2b therapy was the best predictor for response in these patients.
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INTRODUCTION
Chronic infection with hepatitis B virus (HBV) affects approximately 400 million people
worldwide1, 2, and is usually associated with continuing inflammatory activity and progression
of liver disease, which in turn leads to increased risk of cirrhosis, decompensated liver
disease and hepatocellular carcinoma 2, 3.
Therapy with lamivudine establishes high initial response rates, but reappearance of wild-
type HBV occurs in up to 50%-60%  of patients after cessation of therapy4. Continuous
treatment with nucleoside analogues has been associated with the emergence of mutations
in the polymerase genome which cause viral resistance5, 6. Standard interferon alfa (IFN)
therapy has been shown to convert a state of active disease into inactive disease (HBeAg
seroconversion) in about 20-30% of HBeAg-positive chronic hepatitis B patients1, 7.
For the growing population of chronic hepatitis B patients who do not exhibit a sustained
response to antiviral therapy with IFN or lamivudine, it is important to assess whether
retreatment with either IFN or peginterferon is effective. Studies of retreatment with
conventional IFN or lamivudine in previous non-responders to IFN therapy yielded
disappointing HBeAg clearance rates8-11. Recently, studies in HBeAg-positive patients showed
efficacy in 30-40% after one year of treatment with peginterferon alone or in combination
with lamivudine12-14. We studied the efficacy of peginterferon alfa-2b (Peg-IFN α-2b) in
previous non-responders to conventional IFN or lamivudine treatment.
MATERIALS AND METHODS
Patients and methods
For this study, we extracted the data from a multicenter randomized controlled trial which
compared Peg-IFN α-2b mono-therapy to Peg-IFN α-2b combination therapy with lamivudine
for chronic hepatitis B13. Patients received in a 1:1 ratio 100 µg Peg-IFN α-2b weekly with
placebo or with 100 mg lamivudine daily for 52 weeks. After 32 weeks the dose of Peg-IFN
α-2b was halved into 50 µg in order to prevent side-effects and early treatment dis-
continuation. Follow-up after therapy lasted 26 weeks. The inclusion and exclusion criteria
were reported previously13. Major inclusion criteria were: HBeAg-positive on two occasions
within 8 weeks of randomization, elevated serum alanine aminotransferase (ALT) at least
twice the upper limit of normal (ULN), and serum HBV DNA > 105 copies/mL.
The original study contained 266 patients13 of whom 190 were treatment naive and 76
previously treated with IFN and or lamivudine. The analysis of the current study was based
on the 76 patients who had previously received antiviral therapy. Among these, 37 were
non-responders to standard IFN, 17 to lamivudine, and 22 to both IFN and lamivudine. Of
these 22 patients, 12 had been treated sequentially and 10 had received combination therapy.
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For patients with multiple previous therapies with IFN or lamivudine, only the last course
was analyzed. Response to Peg-IFN α-2b therapy was defined as loss of HBeAg after follow-
up.
During therapy and follow-up, patients were seen monthly for routine examination, as well
as biochemical and hematological assessments. Transaminases were assessed locally and
therefore expressed as times upper limits of normal (ULN). HBV DNA was also assessed
monthly (detection limit 400 copies/ml) using in-house Taqman PCR based on the Eurohep
standard15. HBeAg (AxSYM, Abbott) and HBsAg (AxSYM, Abbott) status were assessed at
week 0, 32, 52 (during treatment) and week 78 (after follow-up). HBV genotype and YMDD
mutation analysis were assessed by Inno-Lipa Assay (Innogenetics).
Statistical analysis
In order to establish predictors for response of the retreated, population the following
variables were tested by univariate logistic regression analysis: baseline ALT, HBV DNA, age,
sex, weight, race, HBV genotype and mode of transmission. Characteristics of previous
treatment with IFN, i.e. cumulative dose, duration of therapy, time between end of previous
therapy and start of new therapy, and type of IFN, were also tested. All variables were
checked for interaction with previous therapy. Those variables with p-value < 0.05 were
retained in the final multivariate logistic regression model. In order to calculate compliance
with therapy, survival analysis by means of the log rank test was performed.
RESULTS
Baseline characteristics of previous non-responders are given in Table 1. Median treatment
duration was 24 weeks (range 8 - 52) for previous standard IFN (median dose 18 MU/
week), and 54 weeks (range 2 - 124) for previous treatment with lamivudine (dose 100mg/
day). Median treatment duration for previous non-responders to both IFN and lamivudine
was 24 weeks (range 3-48) for IFN and 52 weeks (range 4-411) for lamivudine. Median
interval to retreatment was 132 weeks (range 26 - 541) for previous IFN and 61 weeks
(range 26 - 150) for previous lamivudine. Median interval to retreatment for non-responders
to both therapies was 111 weeks (range 32-576) and 42 weeks (range 27-366) for IFN and
lamivudine, respectively. A total of 11 patients had a YMDD-mutant at the start of Peg-IFN
α-2b therapy. The most prevalent HBV genotypes were genotype A and D.
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Loss of HBeAg, HBV DNA response and ALT normalization
The rate of serum HBeAg clearance (response), HBV DNA negativity (< 400 copies/mL)
and ALT normalization according to the treatment regimen are given in Table 2. Although
patients with prior exposure to lamivudine tended to respond better to Peg-IFN  α−2b
monotherapy, response rates for Peg-IFN α-2b monotherapy and combination therapy
were in general comparable. Therefore, further analysis was performed for both treatment
groups together. Loss of HBeAg at the end of follow-up occurred in 13 of non-responders
to IFN (35%), 5 of non-responders to lamivudine (29%), and 4 of non-responders to IFN
and lamivudine (18%) (Figure 1). Among the non-responders to IFN, 11 of the 13 with
HBeAg loss developed anti-HBe (85%); all responders of the previous lamivudine group
and in the previous IFN and lamivudine group developed anti-HBe. Among all prior non-
responders HBsAg loss occurred only once (1%; non-responders to lamivudine). In
comparison, HBsAg loss occurred in 17 of the treatment-naive patients (9%), (p = 0.03).
HBV DNA negativity was found in 2 (5%) of the previous IFN non-responders and in 1
(5%) of the lamivudine non-responders. Normalization of ALT occurred in 9 non-responders
to IFN (24%), 7 non-responders to lamivudine (41%), 3 of non-responders to IFN and
lamivudine (14%), and 71 (37%) naïve patients. Of the 11 patients with a YMDD at start of
therapy, 2 (18%) were HBeAg-negative at the start end of follow-up. 
 Peg-IFN α2b  
Lamivudine 
Peg-IFN α2b 
Placebo 
P value 
HBeAg clearance    
 Naive 35/92 (38%) 38/98 (39%) 0.91 
 Previous IFN 8/19 (42%) 5/18 (28%) 0.36 
 Previous LAM 1/9 (11%) 4/8 (50%) 0.13 
 Previous IFN and LAM 2/10 (20%) 2/12 (17%) 1.0 
ALT normalization    
 Naive 34/85 (40%) 37/88 (42%) 0.79 
 Previous IFN 5/19 (26%) 4/18 (22%) 1.0 
 Previous LAM 4/9 (44%) 3/8 (47%) 1.0 
 Previous IFN and LAM 3/10 (30%) 0/12 (0%) 0.08 
HBV DNA < 400 copies/ml    
 Naive 9/83 (11%) 9/87 (10%) 0.91 
 Previous IFN 2/17 (12%) 0/14 (0%) 0.49 
 Previous LAM 1/7 (14%) 0/8 (0%) 0.47 
 Previous IFN and LAM 0/9 (0%) 0/8 (0%) NA 
Table 2. HBeAg clearance, ALT normalization and HBV DNA < 400 copies/mL at the end of
follow-up according to previous treatment
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Response prediction
In order to be able to determine predictors for response (loss of HBeAg at the end of
follow-up), we performed logistic regression analysis for the combined group of previous
non-responders (n=76). Among all prior non-responders, the baseline ALT level was the
only significant parameter predicting response (Table 3). Treatment allocation, baseline HBV
DNA level and  HBV genotype were not associated with response of previous non-
responders. Multivariate analysis confirmed higher baseline ALT levels as an independent
predictor for response. Figure 2 shows the response probability for all groups. In particular
non-responders to prior IFN therapy with baseline ALT above 4 x ULN (n=17) responded
better to Peg-IFN α−2b therapy than those with ALT levels below 4 x ULN (n=20; 53% vs.
20%, respectively, p = 0.036). Among non-responders to previous lamivudine, patients with
ALT above 4 x ULN responded in 50% vs. 18% of patients with baseline ALT below 4 x
ULN (p = 0.28); among non-responders to IFN and lamivudine, corresponding response
rates were 30% and 8%, (p = 0.29), respectively.
Figure 1. HBeAg loss, HBeAg seroconversion, ALT normalization, and HBV DNA response in naive
patients (n=190), IFN nonresponders (n=37), lamivudine non-responders (n=17), and non-responders
to both IFN and lamivudine (n=22) at the end of follow-up. HBeAg loss and ALT normalization: naive
versus non-responders to both IFN and LAM, p = 0.07 and p = 0.02, respectively.
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Baseline hazard ratio 
95% CI 
 lower bound          upper bound p-value 
Age per 10 yrs 0.89 0.60 1.31 0.55 
Weight per 10 kg 1.10 0.74 3.11 0.66 
ALT (x ULN)* 1.27 1.08 1.51 0.005 
ALT (x ULN) > 4  4.55 1.51 13.5 0.006 
Log HBV DNA** 0.90 0.48 1.69 0.74 
Log HBV DNA > 9 0.75 0.27 2.13 0.59 
HBV genotype   
 A 
 B 
 C 
 D 
 Other 
 
1.0 
1.9 
0.002 
0.91 
1.53 
 
 
0.25 
0.000 
0.26 
0.21 
 
 
13.9 
- 
3.24 
11.0 
 
 
0.54 
0.76 
0.88 
0.67 
Combination Rx † 1.03 0.62 1.71 0.90 
Previous duration 
Lamivudine 0.99 0.96 1.01 0.29 
Previous duration IFN 1.01 0.94 1.08 0.92 
Previous dose IFN 1.0 0.99 1.0 0.32 
Table 3. Univariate analysis predicting response of all previous non-responders (N = 76)
**RR per increase of 1 × ULN; † RR per increase of 1 log;
‡ 100 µg Peg-IFN α-2b + 100 mg  lamivudine.
All variables were checked for interaction with previous treatment.
Figure 2. Baseline ALT in serum and probability of response. Response to Peg-IFN α-2b among
non-responder (NR) increases with higher baseline ALT levels. In particular, ALT baseline levels
above 4  xULN improve probability of response. Baseline ALT levels are less predictive for response
in previous non-responders to both IFN and lamivudine.
1086420
1,0
,8
,6
,4
,2
0
IFN NR (n= 37), p = 0.037
Lam NR (n= 17), p = 0.159
IFN/Lam NR (n= 22), p = 0.206
Baseline ALT (xULN)
R
es
po
ns
e 
pr
ob
ab
ili
ty
74
C
ha
pt
er
 5
Safety and adherence
The frequency of adverse events for this population, irrespective of exposure to previous
antiviral therapy, has been described elsewhere13. Anorexia was seen more often in naive
patients (19%) than in the retreated patients (9%, p = 0.05). Occurrence of all other adverse
events was comparable for the retreated and the naive population. Among previous non-
responders, local reaction at the Peg-IFN α-2b injection site was found for 19 of 59 (32%)
non-responders to an IFN-based regimen versus 1 of 17 (6%) non-responders to lamivudine
alone (p = 0.03). Overall, treatment with Peg-IFN α-2b was discontinued early in 24 cases
(9%). Thirteen were naive patients (7%) and 11 retreated patients (14%; p = 0.05; Figure 3).
Also the frequency of Peg-IFN α-2b dose reduction was higher, although not significant, in
retreated patients (Figure 3). Neutropenia was the most frequent cause for dose reduction.
Among the previous non-responder groups, no differences in early treatment discontinuation
were found: 8 non-responders to an IFN-based regimen (14%) and 3 non-responders to
lamivudine alone (18%, p = 0.7) stopped treatment early.
Dosemodification
Weeks
 Early  treatment discontinuation
Naive
NaivePrevious NR
Previous NR
p = 0.05
p = 0.32
0 16 5232 0
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Figure 3. Early treatment discontinuation and dose reduction of Peg-IFN α-2b therapy in naive and
retreated patients. Early treatment discontinuation was seen more often among retreated patients
(p = 0.05). A similar trend was found for dose reduction of Peg-IFN α-2b therapy (p = 0.32).
DISCUSSION
The efficacy of Peg-IFN α-2b alone or in combination with lamivudine in previous non-
responders to standard IFN or lamivudine therapy has not been investigated to date. In the
current study, we found loss of HBeAg in 35% of non-responders to prior IFN, 29% of non-
responders to prior lamivudine, and 18% of non-responders to prior IFN and lamivudine.
Combination of Peg-IFN α-2b and lamivudine did not lead to higher response rates at the
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end of follow-up than Peg-IFN α-2b alone for any of the previous non-responder groups.
Compliance with Peg-IFN α-2b therapy among patients previously treated with IFN or
lamivudine was high, but early treatment discontinuation was more frequent among retreated
than naive patients. The safety profile was comparable for naive and retreated patients.
In the past, repeated use of standard lymphoblastoid IFN alfa treatment for 4 months led to
loss of HBeAg in only 11% of our patients9. The higher response in our present study could
be explained not only by the use of peginterferon, but also by the fact that our previous
study consisted of a difficult-to-treat population with expected low rates of HBeAg loss
based on a response prediction model9. In the current study patients were treated with
peginterferon instead of conventional interferon, which could explain the improved efficacy.
Patients also underwent a longer treatment duration. It may be possible that longer treatment
duration also effected the positive outcome, but we cannot confirm this in the current
study. Another retreatment study in which a 6 months course with standard IFN alfa 2a
was followed by 6 month of follow-up showed HBeAg clearance in 41% of patients (8).
Baseline characteristics to predict treatment response were probably favorable in this
study since the untreated control group exhibited a high HBeAg response rate of 17%.
Lau and colleagues recently reported on the use of peginterferon alfa 2a alone or combined
with lamivudine for HBeAg-positive patients previously exposed to IFN or lamivudine16.
Patients were treated for 48 weeks and assessed 24 weeks after the end of treatment.
Treatment with peginterferon alfa 2a alone resulted in an HBeAg seroconversion rate of
43% for previous IFN non-responders and 32% for previous lamivudine non-responders.
For patients treated with the combination these HBeAg seroconversion rates were 34%
and 25%, respectively. Comparison of these response rates with those found in our study is
difficult since the baseline characteristics were not comparable. Furthermore, for the
peginterferon alfa 2a study, data on dose and duration of previous IFN and lamivudine
exposure as well as the interval between previous therapy and peginterferon alfa 2a therapy,
are not yet available.
In the current study, adding lamivudine to Peg-IFN α-2b did not enhance the response rate
for either treatment-naives or previous non-responders. The efficacy of lamivudine for
previous non-responders to IFN has been poorly examined so far. A study by Schiff et al.
reported an HBeAg clearance rate of 32% after 52 weeks of lamivudine and 16 weeks of
post-treatment follow-up11. This response rate is within the same range as the 35% HBeAg
loss 26 weeks after combination therapy for IFN non-responders in our study. Nevertheless,
the off-treatment sustainability of both HBV DNA and HBeAg response after lamivudine
monotherapy has been debated and long-term follow-up studies are necessary4, 17. The
recent study by Lau et al. with 24 weeks of follow-up after one year of lamivudine showed
a sustained HBeAg seroconversion response of only 13%16.
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In an attempt to predict which previous non-responders benefit most from Peg-IFN α-2b
treatment, we performed a multivariate logistic regression analysis. Among the previous
non-responders to IFN, response to therapy with Peg-IFN α-2b was significantly higher for
patients with baseline ALT levels above 4 x ULN compared to lower than 4 x ULN. A
similar trend was found for non-responders to lamivudine. An approach for repeated therapy
is to follow the patient until the moment when ALT values are above the level of 4 x ULN;
initiating Peg-IFN α-2b therapy may then result in approximately 50% HBeAg response
rates. Our analysis did not show duration and dose of previous therapy as predictors for
response in our study, nor did HBV genotype or baseline HBV DNA level significantly
influence response. In the original study HBV genotype and baseline HBV DNA level were
important predictors for response13, but not in the current study. Since our patient population
consisted previous non-responders - even with a more favorable genotype or previous
HBV DNA level - the positive predicting effect of these variables probably fainted. In addition,
the majority of the present population had very high HBV DNA levels which could explain
that HBV DNA at baseline did not influence the outcome. The importance of inflammatory
activity rather than viral factors suggests that the actual state of the host immune reactivity
is important to achieve response with Peg-IFN α-2b. The limited HBsAg clearance after
(Peg)-IFN therapy among our non-responders and those studied previously8, 11 further
underlines the concept that the non-responder population may be predominantly in some
state of immune tolerance and only transition to pre-treatment immune reactivity predisposes
patients to undergo HBeAg clearance during Peg-IFN α-2b therapy.
In conclusion, Peg-IFN α-2b is effective in approximately one-third of previous non-
responders to IFN or lamivudine therapy. Patients with prior exposure to IFN could be at
risk for early Peg-IFN α-2b treatment discontinuation. High baseline ALT levels are the best
predictors for response. Particularly, in previous non-responders with ALT levels above 4 x
ULN, Peg-IFN α-2b therapy should be considered.
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ABSTRACT
Background/Aims: To determine the response to pegylated interferon-α treatment of HBeAg-
positive hepatitis B patients with proven lamivudine resistance.
Methods: Sixteen HBeAg-positive HBV patients with YMDD mutations were treated with
pegylated interferon. Median treatment duration was 52 weeks (range 20–53), with a 26-
week follow-up.
Results: Two of 16 (12.5%) patients seroconverted to HBeAg negative and achieved sustained
virological (HBV-DNA levels below 10log5 copies/ml) together with biochemical
(normalization of serum ALT levels) responses. Compared with the strong signal in all
other patients, only these two patients had a faint signal in the lamivudine resistance assay.
For all patients, the median viral load decreased from 10log 9.4 to 7.9 copies/ml (p = 0.001)
during treatment but rebounded to a median of 10log 8.7 copies/ml after treatment cessation.
Similarly, elevated median ALT levels at baseline decreased with treatment but rebounded
after the end of treatment.
Conclusions: In the largest cohort study to date, pegylated interferon-α therapy showed
marginal efficacy in the presence of lamivudine resistance but such therapy may be beneficial
in patients with only small amounts of mutant virus. In our opinion, an analysis of the
patient subgroup harbouring an YMDD-mutation should be included in all future studies of
pegylated interferon-α in chronic hepatitis B.
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INTRODUCTION
Although 350–400 million people worldwide are affected by hepatitis B, to date, treatment
for patients is frequently unsuccessful. Chronic hepatitis B is an immunological- based liver
disorder, and there is increasing evidence that only a complete and vigorous HBV-specific
immune response can achieve control and elimination of the virus, preventing disease
progression1. The subgroup of HBeAg-positive hepatitis B patients with proven lamivudine
resistance are little studied, and existing studies are often hampered by their extent and
design2–5, which makes it difficult to draw definitive conclusions about the optimal treatment
for this group. In the study reported here, which is the largest cohort study to date, we
investigate the response of HBeAg-positive hepatitis B patients with proven lamivudine
resistance to pegylated interferon-α.
The nucleoside analogue lamivudine is an effective inhibitor of viral DNA polymerase. It
suppresses replication of HBV, improving transaminase levels and liver histology and enhancing
the loss of hepatitis B e-antigen (HBeAg)6,7. However, sustained response after discontinuation
of treatment occurs in only 10–15% of lamivudine-treated patients 8. Another drawback is
the emergence of mutations, in the tyrosine–methionine–aspartate–aspartate (YMDD-
motif) of the viral polymerase, which are associated with resistance9. Mutations sometimes
arise as little as 6 months after initiation of treatment5 with a resistance rate of 15–30%
after 1 year, increasing to approximately 60–70% after 4 years of continuous treatment
6,7,10–13. Some patients who experience virological breakthrough may develop acute
exacerbation, leading to liver decompensation and death9.
European guidelines recommend pegylated interferon-α as first-line treatment for both
HBeAg-positive and -negative patients13 but there remain several unanswered questions
related to its uptake as a panacea treatment for hepatitis B. There is conflicting evidence on
the effect lamivudine resistance, caused by mutations in the YMDDmotif, on the outcome
of pegylated interferon-a therapy. Recently, our department coordinated a large, independent,
randomised, double-blind multicentre trial to determine the effects of pegylated interferon-
a treatment in HBeAg-positive patients either alone or in combination with lamivudine14.
The presence of the complete data set and patient samples from this trial enabled us to
devise this retrospective cohort study of the outcome of pegylated interferon-a treatment
in HBeAg-positive patients carrying the YMDD-motif mutated virus, which is reported
here.
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PATIENTS AND METHODS
Study design
In this retrospective, comparative, cohort study, data were compiled from the patient files
and virological records of a large, multicentre trial previously conducted in our department
in which the efficacy of pegylated interferon α-2b, either alone or in combination with
lamivudine, was compared in a randomised trial of chronic hepatitis B patients14. In addition,
patients treated by the same protocol outside this study were also included.
Inclusion and exclusion criteria
Eligible patients were HBeAg-positive with resistance to lamivudine as a result of lamivudine
treatment before the start of interferon therapy. Resistance was confirmed by detection of
a mutation in the YMDD motif of the RNA-dependent DNA polymerase gene of the virus.
All patients with lamivudine-resistant virus were included in this analysis, regardless of
differences in the subsequent interferon therapy (mono- or combination therapy). If
mutational data were not available on record, retrospective analysis was carried out on the
corresponding stored serum samples. Where a time point was missing from the records,
results from the nearest date of sampling were taken, within an interval of 4 weeks. Patients
were excluded from the study if they were receiving antiviral treatment at the time of
enrolment in the original study.
Treatment and outcome measures
All patients were treated with pegylated interferon α-2b either in monotherapy (100 µg/
week) or in combination with lamivudine (lamivudine 100 mg/day) for more than 20 weeks
and were followed-up for at least a further 16 weeks post-therapy. During treatment and
follow-up, patients attended outpatient clinics every 4 weeks for routine examination and
laboratory tests. Assessments were made at baseline, Weeks 16, 32 and 52, and after 26
weeks of followup, as appropriate. Outcome measures were assessed at the end of treatment
(Week 52) and at the end of follow-up (Week 26). The primary outcome measure was loss
of HBeAg from serum. Secondary outcomes were return to normal of serum ALT levels,
concentrations of HBV DNA below 200,000 copies/mL and concentrations of HBV DNA
below the level of detection of the assay (Taqmanw assay; 400 copies/mL).
Biochemical and virological assessments
Viral load was determined by HBV DNA serum levels and seroconversion by the presence
of HBeAg or anti-HBe. HBeAg and anti-HBe concentrations were determined using a
Microparticle Enzyme Immune Assay (MEIA, Abbott, Chigaco, IL). During treatment with
interferon, HBV-DNA serum levels were determined by an in-house qPCR (Taqmanw assay)
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calibrated using Eurohep HBV DNA standards15. Used quantitatively, the Taqman assay
enables accurate determination to levels of 1000 copies/mL16. HBV genotypes and mutation
analysis of the YMDD motif at the rtM204M side of the viral polymerase gene were
determined using the Inno-Lipa assay (Innogenetics Ghent, Belgium). The extent of liver
inflammation was determined by measuring serum alanine aminotransferase (ALT) levels.
To correct for the heterogeneity of local assays, ALT levels are expressed as values
representing a ratio to local upper limit of normal (xULN) and shown as medians with
their range.
Statistical analysis
Continuous variables are expressed as median with their range. Median scores were
compared by Wilcoxon Signed-Rank Test. The Mann–Whitney test was used for the
comparison of groups. A two-tailed p-value of < 0.05 was considered statistically significant.
All analyses used SPSS (version 12.0.1; Chicago, IL, USA). Subgroup analyses were performed
to determine whether known predictors of response to therapy accounted for response
to pegylated interferon treatment in this study. The most frequently cited predictors of
response include; previous interferon-alfa treatment, genotype, high ALT levels and low
viral load13,14.
RESULTS
Sixteen HBeAg-positive patients fulfilled the study criteria. The baseline characteristics of
the patients are shown in Table 1. Of the patients in this analysis, the majority (12/16)
received pegylated interferon-α treatment monotherapy and the remaining four were treated
with the same weekly dose of pegylated interferon together with 100 mg of lamivudine per
day (combination therapy). Fifteen of the 16 patients received treatment for 52 weeks and,
for 13 patients, all data (ALT, HBV-DNA and e-status) were available at 26 weeks of follow-
up. In viral samples from two patients only faint mutation bands were visible by the Inno-
Lipa Assay.
HBeAg-status
Two of 16 patients (12.5%; 95% CI—6.0 to 31%) seroconverted to HBeAg negative, and
these two patients also had a sustained virological and biochemical response (HBV-DNA
levels less than 105 copies/ml and normal ALT at 26 weeks follow up)
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Response assessed by ALT measurements
At baseline all patients had elevated ALT levels and a high viral load Ttable 1). By Week 52,
ALT levels decreased to a median of 1.3 xULN (range 0.9–11.6), which is significant compared
with baseline (p = 0.047)(Table 2).
After discontinuation of treatment, ALT levels increased to a median of 2.3 xULN (range
0.9–5.1) by 26-weeks of follow-up. Only 3 (19%) patients had sustainable normal ALT
levels.
Sustained response
By 26 weeks of follow up only 2 of 16 (12.5%; 95% CI- 6.0 to 31%) patients could be
considered as sustained responders to treatment with pegylated interferon alfa by our
primary outcome measure, and only 2/13 (15.4%) patients had viral load below 105 copies/
mL. Only one responder had a HBV DNA less than 400 copies/mL at the end of follow-up.
It is of note that the two responders were the patients where only very faint mutation
bands were visible in the initial Inno-Lipa assay. Both responders were 48 years of age, an
Asian male, interferon naive and a Caucasian male who had received prior interferon-a
therapy. Time elapsed after discontinuation of lamivudine was 64.5 and 31.0 weeks and
fibrosis according Ishak was 5 and 1, respectively. One patient had genotype B and the
other genotype A. Both harboured the M552M + M552I mutation. ALT levels were 7.2 and
4.2 times elevated and HBV DNA levels were 9.1 and 9.7 10log copies/ml, respectively.
None of the baseline characteristics was found to be significantly different compared to the
nonresponders. One other patient had a normal ALT level after 26 weeks of follow up, but
no HBe-seroconversion and HBV DNA above 105 copies/mL.
Monotherapy or combination therapy
The majority of the patients 12/16 (75%) were treated with pegylated interferon α-2b
monotherapy. The baseline characteristics of these patients did not differ significantly from
those receiving combination therapy (Table 1).
After 52 weeks of treatment the ALT levels had decreased equally in both groups (p =
0.791). In the combination therapy group, ALT levels continued to decrease during follow-
up and the median ALT level was normal at end of follow-up which was significantly lower
(p = 0.05) (Table 2). For the monotherapy group, despite achieving similar ALT levels to the
 Viral load
The median viral load for the whole patient group decreased by 1.5 10log copies/ml to 7.9
(range 1.7–10.0) during the treatment period (p = 0.001). However, this reduction was not
sustained and by 26 weeks after treatment cessation the viral load rebounded to a median
of 8.7 10log copies/ml (range 2.6–10.3) (Table 2).
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combination group at week 52, at the end of follow up the ALT levels increased to 2.5
xULN (Table 2.) Although the decrease in viral replication was more marked in the group
receiving lamivudine in addition to interferon (5.6 10log compared with 1.4 10log copies/mL)
during treatment, by 26-weeks after therapy overall viral levels for both groups were not
significantly different (p = 0.643) (Table 2).
None of the 12 (0%) patients receiving pegylated interferon α-2b monotherapy had e-loss,
normal ALT level or HBV DNA level below 105 copies/mL at the end of follow-up. Both
responders were in the group that received combination therapy.
DISCUSSION
This is the largest study to date on the response to pegylated interferon-α treatment of
HBeAg-positive hepatitis B patients who have YMDD-mutated virus after previous lamivudine
treatment. Previous studies with this patient group used non-pegylated interferon-α and
were limited in the number of patients studied2–4, the length of treatment (6 months) and
treatment schedules. The small number of responders to treatment prevented us from
drawing definitive conclusions about the benefits of interferon therapy in this group. In
contrast to the previous studies, in our larger study, all patients were treated with pegylated
interferon-a for 52 weeks, in accordance with present guidelines and recommendations13,17.
In our group of 16 patients, 2 (12.5%) responded positively to pegylated interferon-α
treatment with HBeseroconversion, a drop in viral load and normalization of ALT levels.
This response is lower than that observed in other trials of pegylated interferon-a treatment
for HBeAg-positive patients, where the percentage of e-loss was over 30%14,18. However,
the response rate was in line with that observed in the earlier trials with lamivudine-
resistant patients, where between 16 and 22% of patients responded to pegylated interferon-
α2–5. If we limit the analysis to the patients receiving monotherapy peginterferon-α none of
the 12 (0%) responded to therapy.
There are several proposed predictors of response to treatment with interferon, including;
previous interferon-a treatment, genotype, high ALT levels and low viral load13,14. In this
small study we performed a sub-group analysis to determine which, if any, could explain the
observed marked lack of response to pegylated interferon-α. None of these predictors
were found to influence treatment outcome. We previously found that rate of e-loss was
25% in patients with genotype D virus, compared with 47% in those with genotype A19.
Other studies concur that genotypes C and D are less responsive to interferon-α treatment
compared with genotypes A and B20–23. A large randomised trial with pegylated interferon
α-2a found no significant difference for response according to genotype; however, a trend
for higher responses in patients with genotype A was observed18. In our study of patients
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carrying YMDD-mutated virus, the relationship between genotype and treatment response
was unclear. Both responders had genotypes that respond more favourably to treatment
(genotypes A and B).
In our study it was striking that all patients with clear lamivudine resistance were unresponsive
to interferon therapy. Notwithstanding the possibility that other unidentified factors may
have influenced outcome, and although immunomodulatory therapy has not previously
been linked to therapy failure with nucleoside analogues24, the findings in our study may
suggest that YMDDmutation impairs the immune response to HBV and reduces the efficacy
of pegylated interferon-α treatment. In support of our putative explanation, both responders
had, in contrast to the other subjects, very faint bands in the Inno-LiPA assay, which has a
detection limit of about 5%. This assay was not formally quantified but this qualitative assay
suggests that these patients had only a low quantity of mutant virus. Our results might
suggest that, for subjects with emerging lamivudine resistance, early pegylated interferon-
a therapy may be beneficial. Alternatively, other nucleoside analogues, such as adefovir,
tenofovir and entecavir, which have been shown to be effective against lamivudine-resistant
virus, may present a treatment option for this patient group25–27.
Although suggestive of the negative impact of the presence of the YMDD-mutation on
pegylated interferon α treatment, this study is too small to yield definitive results. More
data are needed to further determine the effect of the YMDD-mutation on the efficacy of
pegylated interferon-a treatment. Whether peginterferon-α combination therapy with other
nucleoside/nucleotide analogues is beneficial for patients with lamivudine resistance has to
be determined. This study is too small to make definite conclusions. The timing of the
therapy may be of importance as both responders receiving combination therapy had only
ittle amounts of mutant virus present in a sensitive assay. In our opinion, an analysis of the
patient subgroup harbouring an YMDD-mutation should be included in all future studies of
peginterferon in chronic hepatitis B.
91Peginterferon after lamivudine resistances
ACKNOWLEDGEMENTS
We acknowledge the HBV 99-01 study group for cooperation within this project.
92
C
ha
pt
er
 6
REFERENCES
1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol
1995;13:29–60.
2. Pariente A, Tachet A, Poveda JD. Treatment of lamiduvine-resistant mutant chronic
hepatitis B with interferon alpha. Gastroenterol Clin Biol 2002;26:1059–1060.
3. Danalioglu A, Kaymakoglu S, Cakaloglu Y, Demir K, Karaca C, Durakoglu Z, et al.
Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis
B. Int J Clin Pract 2004;58:659–661.
4. Ersoz G, Akarca US, Gunsar F, Karasu Z, Batur Y. Interferon retreatment for
resistance to lamivudine plus interferon treatment. Turk J Gastroenterol
2003;14:223–227.
5. Suzuki F, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, et al. Interferon for
treatment of breakthrough infection with hepatitis B virus mutants developing
during long-term lamivudine therapy. J Gastroenterol 2002;37:922–927.
6. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of
lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J
Med 1998;339:61–68.
7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine
as initial treatment for chronic hepatitis B in the United States. N Engl J Med
1999;341:1256–1263.
8. Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, et al. Long-term
efficacy of interferon alpha-2b and lamivudine in combination compared to
lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter,
randomized trial. J Hepatol 2001;35:406–411.
9. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients
with chronic hepatitis B. J Gastroenterol Hepatol 2002;17:S333–S337.
10. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended
lamivudine therapy in Asian patients with chronic hepatitis B. Asia hepatitis lamivudine
study group. Gastroenterology 2000;119:172–180.
11. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine
treatment in patients with chronic hepatitis B enhances hepatitis B e antigen
seroconversion rates: results after 3 years of therapy.
Hepatology 2001;33:1527–1532.
12. Chang TT, Lai CL, Chien RN, Guan R, Lim SG, Lee CM, et al. Four years of lamivudine
treatment in Chinese patients with chronic hepatitis B.
J Gastroenterol Hepatol 2004;19:1276–1282.
13. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, et al. EASL
international consensus conference on hepatitis B. 13–14 September, 2002 Geneva,
Switzerland. Consensus statement (long version). J Hepatol 2003;39:S3–S25.
14. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al.
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-
positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123–129.
93Peginterferon after lamivudine resistances
15. Heermann, K.H., W.H. Gerlich, M. Chudy, S. Schaefer, and R. Thomssen, Quantita
tive detection of hepatitis B virus DNA in two international reference plasma
preparations. EurohepPathobiology Group. J Clin Microbiol, 1999. 37(1): p. 68-73.
16. Pas, S.D., E. Fries, R.A. De Man, A.D. Osterhaus, and H.G. Niesters, Development of
a quantitative real-time detection assay for hepatitis B virus DNA and comparison
with two commercial assays. J Clin Microbiol, 2000. 38(8): p. 2897-901.
17. Cooksley, G., The treatment of hepatitis B e antigen-positive chronic hepatitis B
with pegylated interferon. J Hepatol, 2003. 39 Suppl 1: p. S143-5.
18. Lau, G.K., T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, et al.,
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic
hepatitis B. N Engl J Med, 2005. 352(26): p. 2682-95.
19. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-
2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV
genotype. Am J Gastroenterol. 2006 Feb;101(2):297-303.
20. Wai, C.T., C.J. Chu, M. Hussain, and A.S. Lok, HBV genotype B is associated with
better response to interferon therapy in HBeAg(+) chronic hepatitis than geno
type C. Hepatology, 2002. 36(6): p. 1425-30.
21. Kao, J.H., P.J. Chen, M.Y. Lai, and D.S. Chen, Hepatitis B genotypes correlate with
clinical outcomes in patients with chronic hepatitis B. Gastroenterology, 2000.
118(3): p. 554-9.
22. Kao, J.H., N.H. Wu, P.J. Chen, M.Y. Lai, and D.S. Chen, Hepatitis B genotypes and the
response to interferon therapy. J Hepatol, 2000. 33(6): p. 998-1002.
23. Cooksley, W.G., T. Piratvisuth, S.D. Lee, V. Mahachai, Y.C. Chao, T. Tanwandee, et al.,
Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e
antigen-positive chronic hepatitis B. J Viral Hepat, 2003. 10(4): p. 298-305.
24. Lin, C.L., S.L. Tsai, T.H. Lee, R.N. Chien, S.K. Liao, and Y.F. Liaw, High frequency of
functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expan
sion correlates with successful response to lamivudine therapy for chronic hepa
titis B. Gut, 2005. 54(1): p. 152-61.
25. Perrillo, R., H.W. Hann, D. Mutimer, B. Willems, N. Leung, W.M. Lee, et al., Adefovir
dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant
hepatitis B virus. Gastroenterology, 2004. 126(1): p. 81-90.
26. Levine, S., D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer, et al.,
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and
recombinant polymerases in vitro. Antimicrob Agents Chemother, 2002. 46(8): p.
2525-32.
27. Sherman, M., C. Yurdaydin, J. Sollano, M. Silva, Z. Goodman, L. Chen, et al., Entecavir
is Superior to Continued  Lamivudine for the Treatment of Lamivudine-refractory,
HBeAg(+) Chronic Hepatitis B: Results of Phase III Study ETV-026. Hepatology,
2004. 40(4, Suppl.1): p. 664A.
94
C
ha
pt
er
 7
95Relapse after Peginterferon α-2b in HBeAg positive chronic HBV
Chapter 7
Relapse after treatment with peginterferon alfa-2b
alone or in combination with lamivudine in
HBeAg- positive chronic hepatitis B
H. J. Flink1, E. H. C. J. Buster1, I. Merican2, F. Nevens3, K. J. van Erpecum4;
G. Kitis5, J. Cianciara6, R. A. de Vries7, B. E. Hansen1,8, H. L. A. Janssen1
1. Department of Gastroenterology and Hepatology, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, The Netherlands
2. Hospital Selayang, Institute for Medical Research, Kuala Lumpur, Malaysia
3. Department of Hepatology, University Hospital Gasthuisberg, Leuven,
Belgium
4. Department of Gastroenterology, University Medical Center Utrecht,
Utrecht, The Netherlands
5. Department of Gastroenterology, George Papanikolaou General
Regional Hospital, Thessaloniki, Greece
6. Department of Hepatology, Medical Academy of Warsaw, Warsaw, Poland
7. Department of Gastroenterology, Rijnstate Hospital, Arnhem,
The Netherlands
8. Department of Epidemiology and Biostatistics, Erasmus MC,
University Medical Center Rotterdam, Rotterdam, The Netherlands
Submitted
96
C
ha
pt
er
 7
97Relapse after Peginterferon α-2b in HBeAg positive chronic HBV
ABSTRACT
Background: Interferon-induced loss of HBeAg is generally durable in chronic hepatitis B
infected patients. We investigated the frequency of relapse after peginterferon alfa-2b (Peg-
IFN α-2b) therapy alone or in combination with lamivudine in HBeAg positive patients.
Methods: 266 HBeAg positive patients were treated with Peg-IFN α-2b (100µg/week) with
placebo (n=36) or lamivudine (100mg/day) (n=30) for 52 weeks. Post-treatment follow-up
lasted 26 weeks. Relapse was defined as HBeAg negativity at week 52 and recurrence of
HBeAg at week 78.
Results: HBeAg loss was observed in 44% of patients on combination therapy and 29% on
monotherapy at the end of treatment (p = 0.01). Relapse occurred more often in patients
receiving combination therapy than Peg-IFN α-2b alone (39% vs. 13%, p = 0.005). In the
combination therapy group, relapse occurred significantly less frequent if anti-HBe was
detectable at the end of treatment (21% vs. 63%, p = 0.002). HBV DNA below 10,000
copies/mL at the end of treatment resulted in a decreased risk of relapse (p = 0.01). In
multivariate analysis, combination therapy (RR 3.9, CI95% 1.1-13.2, p = 0.03), HBsAg positivity
at week 52 (RR 10.3, CI95% 1.09-97.89, p = 0.04) and absence of anti-HBe at week 52 (RR
9.8, CI95% 3.2-30.3, p < 0.001) independently predicted HBeAg relapse.
Conclusion: HBeAg relapse occurs more frequently after Peg-IFN α-2b and lamivudine
combination therapy than after Peg-IFN α-2b monotherapy. Absence of anti-HBe at the
end of treatment was found to be the strongest predictor of relapse. Full HBeAg
seroconversion with appearance of anti-HBe, rather than HBeAg loss, thus seems the best
endpoint of Peg-IFN therapy in HBeAg-positive chronic HBV.
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INTRODUCTION
Sustained loss of hepatitis B e antigen (HBeAg) from serum is associated with loss of
hepatitis B surface antigen (HBsAg), reduced incidence of hepatocellular carcinoma (HCC)
and improved survival1. Treatment with interferon (IFN) for chronic hepatitis B virus (HBV)
infection results in HBeAg loss in about one-third of HBeAg positive patients2. IFN-induced
HBeAg loss is generally durable, with sustained response in up to 90% of patients 1, 3, 4. A
study by Song et al. in a Korean population demonstrated older age and presumed vertical
transmission of HBV to be independent predictors for relapse after conventional IFN
treatment5.
Nucleo(t)side analogues are well capable of inhibiting HBV replication, and have been shown
to induce HBeAg loss in 15-30% of patients after 1 to 2 years of treatment6, 7. However,
prolonged treatment with lamivudine or adefovir is associated with the emergence of
therapy resistant HBV strains and relapse occurs frequently after cessation of treatment
with these drugs8, 9. Predictors for sustained HBeAg seroconversion after lamivudine therapy
include prolonged duration of therapy after HBeAg seroconversion and HBV genotype10.
Shorter duration of undetectable HBV DNA (<0.7 10log IU/mL) was found to predict
relapse after lamivudine therapy11. Increased duration of undetectable HBV DNA by an
additional month reduced the risk of relapse by 50%.
Recently performed studies with one year of pegylated interferon (Peg-IFN) alone or in
combination with lamivudine in HBeAg positive patients showed high baseline alanine
aminotransferase (ALT), low baseline HBV DNA, absence of previous IFN therapy, low
baseline HBeAg and HBV genotype as independent predictors of response12-14. Predictors
for relapse after Peg-IFN therapy are still unknown. In this study we investigated the frequency
and possible predictors of relapse after treatment with Peg-IFN α-2b alone or in combination
with lamivudine.
PATIENTS AND METHODS
Data for this study were extracted from a multicenter randomized controlled trial which
compared Peg-IFN α-2b monotherapy to its combination with lamivudine in patients with
HBeAg positive chronic hepatitis B. The inclusion and exclusion criteria were reported
previously12. In short, patients were eligible if they had been HBsAg positive for more than
6 months, were HBeAg positive on two occasions within 8 weeks prior to randomization,
had elevated serum ALT of at least twice the upper limit of normal (ULN), and had serum
HBV DNA  >1.0 x 105 copies/mL. Major exclusion criteria were: antiviral therapy within 6
months prior to randomization, serum antibodies against hepatitis C virus, hepatitis D virus
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or human immunodeficiency virus (HIV), pre-existent leucopenia or thrombocytopenia
(white blood cell count (WBC)  ≤ 3,000/mm3, neutrophils ≤ 1,800/mm3, platelets  ≤ 100,000/
mm3), or decompensated liver disease.
Patients were randomized in a 1:1 ratio to receive Peg-IFN α-2b (100 µg weekly) with
placebo or with lamivudine (100 mg daily) for 52 weeks. After 32 weeks, Peg-IFN α-2b
dosage was lowered to 50 µg to prevent side effects and early treatment discontinuation.
Follow-up after discontinuation of therapy lasted 26 weeks.
During therapy and post-treatment follow-up, patients were monitored monthly by routine
physical examination, as well as biochemical and hematological assessments. ALT was assessed
locally and therefore expressed as times upper limits of normal (ULN). HBV DNA was
assessed monthly using an in-house developed Taqman PCR assay (lower limit of detection
400 copies/mL) based on the Eurohep standard15. HBeAg and HBsAg (AxSYM, Abbott,
Abbott Park, IL, USA) were assessed at week 0, 32, 52 and week 78 (end of follow-up). HBV
genotype and YMDD mutation analysis were performed by INNO-LiPA Assay (Innogenetics,
Gent, Belgium).
Liver histology was assessed at baseline in all patients. Biopsy at the end of treatment was
optional. Paired biopsies were available for 110 patients. Histological scoring was performed
by one experienced pathologist according to the histological activity index, modified by
Ishak16. The pathologist was blinded for information about the chronological order of biopsies,
treatment allocation and outcome measures. Improvement of histology was defined as a
reduction of at least two points in necroinflammatory score (range 0-18) or one point in
fibrosis score (range 0-6).
Relapse was defined as HBeAg negativity at the end of treatment (week 52) and recurrence
of HBeAg at the end of follow-up (week 78). Post-treatment response was defined as
HBeAg positivity at week 52 and HBeAg negativity at week 78. Virological response was
defined as HBV DNA < 200,000 copies/mL and biochemical response as normalization of
ALT12. For the assessment of virological and biochemical relapse, and post-treatment response,
criteria similar to those for HBeAg response were used. The first time point of biochemical
or virological response was defined as serum ALT >1 xULN or HBV DNA < 200,000
copies/mL on two consecutive occasions, respectively.
Statistical analysis was performed using the SPSS 11.5 program (SPSS Inc. Chicago, IL). Chi-
square, Fisher's exact test and Mann-Whitney U test were used where appropriate. The
relation between patient characteristics at baseline and during therapy, and relapse and
post-treatment response was examined by logistic regression analyses. Univariate analysis
was used to assess the importance of prognostic factors. To investigate the independence
of these factors, multivariate logistic regression analyses was performed with all characteristics
with a p-value < 0.20 in univariate analysis. A p-value < 0.05 was considered statistically
significant (all two-tailed).
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RESULTS
At the end of treatment, 97 of 266 patients (36%) lost HBeAg, 57 (44%) in the combination
therapy group and 40 (29%) in the monotherapy group (p = 0.01). Twenty-seven of these 97
responders (28%) had recurrence of HBeAg at the end of follow-up (relapse), and 70
(72%) remained HBeAg negative throughout post-treatment follow-up (sustained response).
Virological response (HBV DNA <200,000 copies/ml) occurred in 96 (74%) patients receiving
combination therapy and 40 (29%) receiving monotherapy at the end of treatment (p <
0.001); ALT normalization was observed in 66 (51%) and 46 (33%) patients at the end of
therapy, respectively (p = 0.005). Baseline characteristics of patients with HBeAg relapse
and sustained HBeAg response are shown in Table 1. No differences in baseline variables
were found between these groups.
Relapse and post-treatment response for HBeAg, ALT and HBV DNA
HBeAg relapse occurred more often in patients treated with Peg-IFN α-2b and lamivudine
combination therapy compared to Peg-IFN α-2b alone (Figure 1A): 22 patients (39%) in the
combination therapy group and 5 (13%) in the monotherapy group relapsed (p = 0.005).
Post-treatment response occurred in 15% of patients from both treatment groups. Relapse
and post-treatment response rates for biochemical and virological response are shown in
Figure 1B and C. For both endpoints, patients in the combination therapy group more
often relapsed than those in the monotherapy group (p = 0.054 and p = 0.037 for virological
response and biochemical response, respectively). Patients with HBeAg relapse were more
likely to have relapse of HBV DNA >200,000 copies/mL than sustained HBeAg responders
(76% vs. 20%, p < 0.001), as well as relapse of ALT (69% vs. 24%, p = 0.007).
Prediction of HBeAg relapse
Among patients treated with combination therapy, 7 of 33 patients (21%) with detectable
anti-HBe at the end of therapy relapsed compared to 15 of 24 patients (63%) without
detectable anti-HBe (p = 0.002). A similar trend was observed in patients treated with Peg-
IFN α-2b alone, 2 of 30 patients (7%) with detectable anti-HBe and 3 of 7 patients without
(30%) relapsed (p = 0.09). Seven of 10 patients (70%) in the monotherapy group did not
relapse despite the absence of anti-HBe compared to 9 of 24 patients (38%) treated with
combination therapy (p = 0.13). Three patients treated with Peg-IFN α-2b alone (30%) and
4 treated with combination therapy (17%), who had no detectable anti-HBe at the end of
treatment, developed anti-HBe at the end of follow-up (p = 0.39). HBV genotype tended to
influence HBeAg relapse rates, 29% of patients harboring genotype A relapsed compared
to 56% of patients with genotype D (p = 0.09).
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Serum HBV DNA in relation to HBeAg relapse
Mean HBV DNA levels in patients with HBeAg relapse and sustained responders are
shown in Figure 2 for patients treated with Peg-IFN α-2b alone or its combination with
lamivudine. In patients treated with Peg-IFN α-2b alone, combination of HBeAg loss and
HBV DNA <10,000 copies/mL at week 52 was associated with a significantly lower rate of
relapse compared to HBeAg loss alone (0% vs. 63%, p = 0.01), while this difference was not
observed in the combination therapy group. In none of 19 patients treated with Peg-IFN α-
2b alone, who had HBV DNA <10,000 copies/mL for at least 4 weeks prior to discontinuation
of therapy HBeAg relapse occurred, while this occurred in 5 of 20 patients (25%) with HBV
DNA >10,000 copies/mL for at least 4 weeks relapsed (p = 0.04). At the end of follow-up,
56% of patients with sustained HBeAg response had HBV DNA <10,000 copies/mL compared
to 4% of patients with relapse (p < 0.001).
*Mean ± SD. †Median (range).
Table 1. Baseline characteristics of responders at the end of treatment (n=97), divided by the
occurrence of relapse (n=27) or sustained response (n=70) after therapy.
Variable Relapse (n = 27) 
Sustained response 
(n = 70) p 
Age* 36.3 ± 11.1 38.1 ± 12.4 0.50 
Weight* 76.1 ± 14.1 75.6 ± 16.7 0.91 
Race 
Caucasian 
 Asian 
 Other 
 
 
22 (82%) 
4 (15%) 
1 (3%) 
 
52 (74%) 
12 (17%) 
6 (9%) 
 
0.64 
 
 
Serum ALT* 5.5 ± 3.7 4.6 ± 3.0 0.22 
HBV DNA (log10 copies/ml)* 9.0 ± 1.0 8.9 ± 0.9 0.66 
HBV genotype 
 A 
 B 
 C 
 D 
 
 
11 (41%) 
2 (7%) 
2 (7%) 
12 (44%) 
 
35 (50%) 
6 (9%) 
8 (11%) 
16 (23%) 
 
0.22 
 
 
 
Histology † 
 Necroinflammation 
 Fibrosis 
 
5 (2 – 10) 
3 (0 – 6) 
 
6 (2 – 10) 
3 (0 – 6) 
 
0.36 
0.69 
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Figure 1. Relapse and post-treatment
response after Peg-IFN α-2b alone or its
combination with lamivudine. HBeAg
relapse (HBeAg-negative at week 52 and
positive at week 78) occurred significantly
more often after Peg-IFN α-2b and
lamivudine combination therapy com-
pared to treatment with Peg-IFN α-2b
alone (p = 0.005), as well as HBV DNA
relapse (HBV DNA >200,000 copies/mL
at week 78 after initial decline below this
level at week 52, p= 0.054) and ALT
relapse after initial normalization (p =
0.037). Post-treatment response for
HBeAg and HBV DNA <200,000 copies/
ml was observed equally among
treatment groups, while normalization of
ALT occurred more often in patients
treated with Peg-IFN α-2b alone (p =
0.036).
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Figure 2. Mean HBV DNA in patients with HBeAg relapse and sustained response after Peg-IFN α-
2b alone or its combination with lamivudine. Among patients treated with Peg-IFN α-2b monotherapy,
decline in HBV DNA was more pronounced in sustained responders than relapsers (A). This difference
was however not observed in patients treated with Peg-IFN α-2b and lamivudine combination therapy
(B). Mean HBV DNA was comparable in sustained responders and relapsers at baseline in both
treatment groups. In patients treated with Peg-IFN α-2b alone, decline in HBV DNA was 4.8 log10
copies/mL for patients with relapse compared to 3.8 log10 copies/mL for sustained responders at the
end of treatment (p = 0.30). Decline in HBV DNA was 5.8 log10 copies/mL for all patients in the
combination therapy group at the end of treatment. In both treatment groups mean HBV DNA was
significantly higher in relapsers than sustained responders at week 78 (9.2log10 vs. 4.6 log10 for
monotherapy and 7.7 log10 vs. 3.7 log10 for combination therapy, p < 0.001).
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Logistic regression analysis of factors predicting HBeAg relapse and post-treatment HBeAg
response
For the prediction of HBeAg relapse and post-treatment HBeAg response, the following
baseline variables were included in univariate logistic regression analysis: age, sex, weight,
race, mode of transmission, serum ALT, HBV DNA level, HBV genotype and liver histology.
In addition to these baseline variables, treatment allocation, HBeAg and anti-HBe status at
week 32; serum ALT, HBV DNA, anti-HBe, HBsAg (HBeAg relapse only) and liver histology
at week 52; and time points of ALT normalization and HBV DNA response were included
(Table 2). In multivariate time dependent analysis, combination therapy of Peg-IFN α-2b
with lamivudine (RR 3.9, CI95% 1.1 - 13.2, p = 0.03), HBsAg negativity at week 52 (RR 10.3,
CI95% 1.09-97.89, p = 0.04) and absence of anti-HBe at week 52 (RR 9.8, CI95% 3.2 - 30.3,
p < 0.001) independently predicted HBeAg relapse. Absence of anti-HBe at the end of
treatment was found to be the strongest predictor of HBeAg relapse. Weight was found to
be the only independent predictor of post-treatment HBeAg response, higher weight
decreased the likelihood of HBeAg response after discontinuation of therapy (RR 0.92,
95% CI 0.87-0.97, p = 0.003).
Table 2. Factors significantly associated with HBeAg relapse and post-treatment response in
univariate analysis.
Variable Hazard ratio 95% CI   lower  upper p 
Relapse     
Combination therapy 4.4 1.15 12.93 0.007 
Anti-HBe positive week 32 0.29 0.10 0.82 0.02 
Anti-HBe positive week 52 0.15 0.06 0.39 <0.001 
Post-treatment response     
Sex – male 0.25 0.11 0.61 0.002 
Weight 0.95 0.92 0.99 0.01 
Body mass index (BMI) 0.90 0.82 0.99 0.03 
Baseline necroinflammation 1.25 1.00 1.55 0.05 
HBeAg negative week 32 13.16 3.03 57.09 0.001 
Anti-HBe positive week 32 8.03 1.98 32.58 0.004 
Time point of ALT normalization 0.98 0.96 0.99 0.007 
Time point of HBV DNA response 0.98 0.97 1.00 0.009 
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DISCUSSION
In HBeAg-positive chronic hepatitis B, relapse occurs often after discontinuation of
nucleos(t)ide analogue therapy, while response appears more durable after interferon-
based treatment because of its immunomodulatory effects. In the current study we found
39% relapse after discontinuation of Peg-IFN α-2b and lamivudine combination therapy and
13% after Peg-IFN α-2b alone. Observed relapse rates are consistent with findings of
previous studies, which showed HBeAg relapse in 22-40% of lamivudine treated patients3, 17,
and 10% of IFN treated patients3, 18. Most likely, the higher relapse rates (preceded by higher
response rates) after cessation of combination therapy compared to Peg-IFN α-2b
monotherapy can be explained by lamivudine induced HBeAg loss.
In multivariate analysis, absence of anti-HBe and HBsAg-negativity at the end of treatment
independently predicted HBeAg recurrence in addition to treatment allocation. Factors
predicting relapse after conventional IFN have previously been described and include older
age and presumable vertical transmission5. We did not find a relation between relapse and
these factors in both univariate and multivariate analysis. Possibly our findings differ with
findings from this study because of differences in patient population (Asian vs. Caucasian
population) and type or duration of the antiviral therapy.
Among Peg-IFN α-2b and lamivudine treated patients in our study, 21% of those positive
for anti-HBe at the end of therapy relapsed compared to 63% of patients who lacked anti-
HBe. In HBeAg-positive patients treated with Peg-IFN α-2a, HBeAg seroreversion occurred
in 18% of patients treated with Peg-IFN α-2a monotherapy and 22% of patients on
combination therapy with lamivudine19. Response was durable in 86% of responders at 1
year post-treatment in this study20. Although relapse rates in patients without detectable
anti-HBe in our study are much higher compared to Peg-IFN α-2a treated patients with
HBeAg-seroconversion, relapse rates for patients with loss of HBeAg and detectable anti-
HBe at the end of treatment seem comparable between the two studies.
Presence of anti-HBe may be less important for Peg-IFN α-2b monotherapy than combination
therapy, since the majority of patients treated with Peg-IFN α-2b monotherapy (7 of 10
patients) did not relapse despite the absence of anti-HBe at the end of therapy. In patients
with HBeAg relapse, HBV DNA levels declined during treatment, but decline was less
profound compared to sustained responders (Figure 2). HBV DNA <10,000 copies/mL
prior to discontinuation of treatment was found to significantly decrease the risk of relapse
in Peg-IFN α-2b treated patients. This is consistent with findings on relapse after cessation
of lamivudine in patients with prolonged suppression of HBV DNA11. Decline in HBV DNA
(and ALT normalization) may thus be important for maintaining Peg-IFN induced response.
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Patients with a partial response as defined by HBeAg loss but insufficient decline of HBV
DNA (not below 10,000 copies/mL) at the end of therapy, might benefit from prolonged
therapy, as has previously been shown to increase response to conventional IFN21.
Maintaining HBV DNA below 10,000 copies/mL after discontinuation of therapy seems
important since recent studies showed that serum HBV DNA below this level reduces the
risk of progression to cirrhosis, decompensated liver disease and HCC22, 23. Fifty-six percent
of sustained responders had HBV DNA <10,000 copies/mL at the end of follow-up, while
virtually all patients with relapse had HBV DNA above this level. In HBeAg positive patients
treated with monotherapy of Peg-IFN α-2a, a comparable rate of HBV DNA below 10,000
copies/mL was observed in responders (66%) at the end of follow-up24.
HBV genotype independently predicted loss of both HBeAg and HBsAg in HBeAg-positive
patients treated with Peg-IFN α-2b, with higher response rates in patients with genotype A
compared to those with genotype D12, 25. A similar trend was observed in a population of
mainly Asian patients treated with Peg-IFN α-2a19, 26. HBV genotype also tended to influence
HBeAg relapse after discontinuation of Peg-IFN α-2b with or without lamivudine, with
genotype D infected patients having a higher risk of relapse than those with genotype A.
In conclusion, HBeAg relapse occurs more often after treatment of Peg-IFN α-2b in
combination with lamivudine than after Peg-IFN α-2b monotherapy. Absence of anti-HBe
at the end of treatment was found to be the strongest predictor of relapse, particularly in
patients treated with combination therapy. HBeAg loss thus is less suitable as sole endpoint
of Peg-IFN based therapy in HBeAg positive chronic HBV. More profound suppression of
HBV DNA (below 10,000 copies/mL) decreases the risk of relapse. Patients with a partial
response might benefit from prolonged Peg-IFN treatment, further reducing HBV DNA
and thereby possibly increasing the development of anti-HBe and reducing the risk of
relapse after discontinuation of therapy.
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Chapter 8
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113Is weight-based dosing of Peginterferon α-2b in CHB necessary?
ABSTRACT
Weight-based dosing of peginterferon alfa-2b (Peg-IFN α-2b) therapy is probably more
effective than a fixed dose for the treatment of chronic hepatitis C. In this study we
investigated whether body weight was associated with response (HBeAg loss at end of
follow-up) after Peg-IFN α-2b therapy. A total of 266 chronic HBeAg-positive hepatitis B
patients received 100 µg Peg-IFN α-2b weekly for 52 weeks. After week 32 the dose was
halved to 50 µg Peg-IFN α-2b. The post-treatment follow-up lasted 26 weeks.  Using this
fixed dose of Peg-IFN α−2b HBeAg clearance decreased with higher bodyweight until 85
kg: HBeAg response was 46% for ≤ 55 kg (n=26), 42% for 55-65 kg (n=65), 31% for 65-75
kg (n=77), 24% for 75-85 kg (n=58), and 45% for > 85 kg (n=44). Multivariate analysis did
not show interaction between patients > 85 kg and baseline ALT, HBV DNA or previous
treatment with interferon. Among patients >  85 kg, 41% (n=18) harbored genotype A, and
47% (n=21) genotype D. Interestingly, within genotype A, patients > 85 kg responded better
than patients ?85 kg, (83% vs. 39%, p = 0.001), the opposite was found for genotype D, 8%
vs. 29% for patients > 85kg and ≤ 85 kg, respectively, p = 0.06). Body mass index (BMI) was
not significantly different between genotype A (mean BMI = 24) and genotype D (mean
BMI = 24), p = 0.92.
In conclusion, our study indicates that Peg-IFN α-2b should probably be administered on
weight-based dosing regimen for patients harboring genotype D. Weight-based dosing may
not be necessary for patients harboring genotype A. Dose and duration ranging studies are
needed for further optimalization of Peg-IFN α-2b therapy.
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INTRODUCTION
World-wide, approximately 400 million people are chronically infected with the hepatitis B
virus (HBV), and chronic hepatitis B (CHB) infection has become the single most common
cause for decompensated liver disease and hepatocellular carcinoma1. CHB can be treated
with nucleos(t)ide analogues such as lamivudine and adefovir or with (pegylated) interferon.
Pegylated interferons (Peg-IFNs) are already widely used in the treatment for chronic
hepatitis C but have only recently been introduced for the treatment of CHB2-4. For the
treatment of hepatitis C two types of Peg-IFNs have been registered. Peginterferon alfa-2a
(Peg-IFN α-2a) which is administered using a fixed-dose regimen, and peginterferon alfa-2b
(Peg-IFN α-2b) which is weight-based administered. In hepatitis C studies with a fixed-dose
of Peg-IFN α-2a, increased body weight led to a lower rate of sustained virological response5,
6. Another study by Lindsay et al. in which Peg-IFN α-2b was used on a weight-based dosing
regimen, did not show that body weight was a predictive factor for response7.
As yet, it is unknown whether body weight is associated with response in patients infected
with CHB. In a recently conducted study using a fixed-dose of Peg-IFN α-2b for HBeAg-
positive chronic hepatitis B4, we investigated whether body weight was associated with
HBeAg loss at the end of follow-up after treatment with Peg-IFN α-2b with or without
lamivudine.
PATIENTS AND METHODS
For this study, we extracted the data from a multicenter randomized controlled trial which
compared Peg-IFN α-2b mono-therapy to Peg-IFN α-2b combination therapy with lamivudine
in chronic hepatitis B4. The in- and exclusion criteria were reported previously. Major inclusion
criteria were: HBeAg-positive on two occasion8 weeks prior to randomization, elevated
serum alanine transferase (ALT) of at least twice the upper limit of  normal (ULN), and
serum HBV DNA >105 copies/ml. Patients were assigned to 100 µg Peg-IFN α-2b with
placebo or with daily 100 mg lamivudine for 52 weeks. After 32 weeks the dose of Peg-IFN
α-2b was halved into 50µg in order to prevent side effects and early treatment discontinuation.
Patients who weighted ≤ 55kg were treated according to a weight-based regimen (1.5 µg/
kg for the first 32 weeks and 0.75 µg/kg for the remaining treatment period). Dose of Peg-
IFN α-2b for hematological abnormalities was reduced with 50% in the event of neutropenia
(granulocytes < 1.0x 109/L), leucopenia (white blood cells < 2.0 x 109/L), and thrombo-
cytopenia (platelets < 50 x 109/L). Other clinical relevant adverse events associated with
the use of Peg-IFN α-2b (such as depression, fatigue and flu-like-symptoms) were also
reasons for dose reduction. Post-treatment follow-up lasted 26 weeks. During therapy and
follow-up patients were seen every 4 weeks for routine examination and biochemical and
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hematological assessments. Transaminases were determined locally and therefore expressed
as times upper limits of normal (ULN). HBV DNA was also determined 4-weekly using an
in-house Taqman PCR (detection limit 400 copies/mL) based on the Eurohep standard8.
HBeAg (AxSYM, Abbott) and HBsAg (AxSYM, Abbott) status was determined at weeks 0,
32, 52 (during treatment) and at week 78 (end of follow-up). HBV genotype was assessed
by Inno-Lipa Assay, Innogenetics.
Liver histology was assessed at baseline and an optional biopsy was performed at the end
of treatment. Paired biopsies were available for 110 patients. Histological scoring was
performed by one experienced pathologist according to the histological activity index,
modified by Ishak14. The pathologist was blinded for chronological order of biopsies and
treatment schedule. Improvement of histology was defined as a reduction of at least two
points in the necroinflammatory score (range 0-18) and one point of the fibrosis score
(range 0-6). Response was defined as HBeAg loss at the end of follow-up. ALT normalization
and HBV DNA response was defined as serum ALT <1x ULN, and serum viral load <200.000
copies/mL, respectively.
Statistical analysis
All data were analyzed using SPSS version 11.5 (SPSS Inc. Chicago, IL). Chi-square, Fisher's
exact test, and Mann-Whitney U test were used where appropriate. A p value < 0.05 was
considered significant (all two-tailed).
RESULTS
Of the original 266 patients, 264 were categorized in 5 weight categories, ≤ 55 kg (n=26),
55-65 kg (n=59), 65-75 kg (n=77), 75-85 kg (n=58) or >85 kg (n=44). For 2 patients data
on body weight were missing. Mean total dose of Peg-IFN α-2b was 62µg/kg, 58µg/kg, 55µg/
kg, 49µg/kg and 42µg/kg for the different weight groups, respectively. HBeAg clearance was
seen for 46% (n=12) of patients ≤ 55 kg, 42% (n=25) of patients 55-65 kg, 31% (n=24) of
patients 65-75 kg, 24% (n=14) of patients 75-85 kg, and 45% (n=20) of patients >85 kg
(Figure 1). Except for patients > 85 kg HBeAg clearance decreased with increasing body
weight. When excluding patients > 85 kg body weight was significantly associated with
HBeAg clearance (RR 0.97 95%CI 0.95 to 1.00,  p = 0.047). The addition of lamivudine did
not change the response pattern nor HBeAg loss at the end of follow-up. Interestingly,
patients >85 kg responded significantly better than those weighing 75-85 kg (RR 2.6 95%CI
1.1 to 6.1, p = 0.026). A similar trend was found when compared with patients weighing 65-
75kg (RR 1.8 95%CI 0.9 to 4.0, p = 0.12).
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In our previous study with the same population4, we found that higher baseline serum ALT
levels, lower baseline HBV DNA levels, absence of previous IFN treatment and HBV genotype
A were positive predictors for HBeAg loss at the end of follow up. To reveal whether these
baseline variables could explain the marked increase of HBeAg loss at the end of follow-up
of the patients > 85 kg, we performed a univariate analysis between the weight categories
(Table 1). The HBV genotypes were not significantly different between the weight categories.
Logistic multivariate analysis did not show any interaction between the known predictors
for response or other baseline variables and patients > 85 kg.
Among patients > 85 kg 41%  harbored HBV genotype A (n=8) and 47%  D (n=21). As
shown in Table 1, these most common HBV genotypes were not more prevalent among
patients > 85 kg than other weight categories. Interestingly, within genotype A, patients >
85 kg responded better than patients ≤ 85 kg, (83% vs. 39%, p = 0.001), whereas the
opposite was found for genotype D, 8% vs. 29% for patients >85kg and HBeAg loss ≤ 85 kg,
respectively, p = 0.06). Figure 2 shows the relation of body weight and response according
to the HBV genotype A and D. Body mass index (BMI) was not different between genotype
A (mean BMI = 24) and genotype D (mean BMI = 24), p = 0.92. For BMI in relation to
HBeAg loss a similar pattern was found for genotypes A and D.
Table 1. Baseline characteristics according to weight group
Baseline ≤55 kg 
(n = 26) 
55-65 kg 
(n = 59) 
65-75 kg 
(n = 77) 
75-85 kg 
(n = 58) 
> 85 kg 
(n = 44) 
Age* 29 ± 9.9 32 ± 12.7 35 ± 12.6 36 ± 13.5 41 ± 12.4 
Sex – male  4 (15%) 38 (64%) 65 (84%) 54 (93%) 42 (96%) 
Race 
Caucasian 
Asian 
Other  
 
13 (50%) 
12 (46%) 
1 (4%) 
 
39 (66%) 
14 (24%) 
6 (10%) 
 
54 (70%) 
17 (22%) 
6 (8%) 
 
48 (83%) 
8 (14%) 
2 (3%) 
 
40 (91%) 
1 (2%) 
3 (7%) 
HBV Genotype 
A 
B 
C 
D 
other 
 
4 (15%) 
5 (19%) 
6 (23%) 
11 (42%) 
0 
 
12 (20%) 
8 (14%) 
11 (19%) 
25 (42%) 
3 (5%) 
 
29 (38%) 
7 (9%) 
13 (17%) 
24 (31%) 
4 (5%) 
 
25 (43%) 
3 (5%) 
7 (12%) 
22 (38%) 
1 (2%) 
 
18 (41%) 
0 
2 (5%) 
21 (48%) 
3 (7%) 
ALT (x ULN)* 3.8 ± 2.8 4.3 ± 4.5 4.1 ± 2.8 4.3 ± 2.7 5.2 ± 3.8 
Log HBV DNA* 9.0 ± 1.0 8.7 ± 1.3 9.0 ± 0.9 9.4 ± 0.8 9.3 ± 0.7 
Cirrhosis 0 3 (5%) 6 (8%) 7 (12%) 8 (18%) 
Previous IFN 2 (8%) 14 (24%) 15 (20%) 15 (26%) 12 (27%) 
 * Mean ± SD
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Figure 2. Body weight and relation to response probability (HBeAg loss at the end of follow-up).
Among patients with HBV genotype A (black) probability of response increases in patients > 85 kg.
Among patients harboring genotype D (grey) response decrease with increasing body weight.
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Figure 1. HBeAg loss at the end of follow-up (week 78) according to weight category. HBeAg loss
for patients > 85 kg (45%) versus 75-85 kg (24%), p = 0.024.
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DISCUSSION
In contrast with the treatment for chronic hepatitis C in which Peg-IFNs are widely used,
Peg-IFNs for CHB therapy have only been introduced recently2-4, 9. In the treatment for
chronic hepatitis C it is assumed that with a fixed dose of Peg-IFN α-2a higher body
weight-based is associated with a lower sustained virological response5, 6. The role of body
weight in relation to response in chronic hepatitis B has not been investigated yet. In the
current study with fixed dose of Peg-IFN α-2b with or without the addition of lamivudine
we found HBeAg loss for 46% of patients ≤ 55 kg, 42% of patients 55-65 kg, 31% of patients
65-75 kg, 24% of patients 75-85 kg, and 45% of patients >85 kg. Except for patients > 85 kg,
patients tended to have less HBeAg loss at the end of follow-up with increasing body
weight. An interesting finding of the current study was the marked increase in HBeAg loss
in patients > 85 kg. One would expect that with a fixed dose of Peg-IFN α-2b higher body
weight would lead to lower HBeAg loss at the end of follow-up. In previous studies with a
fixed dose of Peg-IFN α-2a (with or without daily ribavirin) for chronic hepatitis C infection,
they found that patients < 85 kg responded better than those ≥ 85 kg5. Fried et al found
that patients ≤75 kg more often had sustained responses than those >75 kg 6. Obviously,
when these results are extrapolated to chronic HBV infection, the comparison of the data
should be made with caution.
Possible confounders (such as high baseline ALT, low baseline HBV DNA, previous IFN and
HBV genotype4), which could explain the marked increase of HBeAg loss in patients > 85
kg could not be identified. Although baseline serum ALT was higher among patients > 85 kg,
the difference was not significant. Also genotype A and D were equally distributed within
patients >85 kg, which rules out the opportunity of over representation of genotype A.
Within these genotypes a remarkable finding was the fact that within genotype A HBeAg
loss at the end of follow-up was very high among patients > 85 kg. Eighty-three percent of
these patients showed HBeAg loss at the end of follow-up. Moreover, the opposite was
found for patients harboring genotype D and > 85 kg. To our knowledge no such data has
been presented on response and weight in relation to HBV genotype. The two large studies
with Peg-IFN α-2a in HBeAg-positive and HBeAg-negative CHB did not report in this topic
either2, 3.
In conclusion, our study indicates that Peg-IFN α-2b should possibly be administered on
weight-based dosing regimen for HBeAg-positive CHB, especially those harboring genotype
D.  Weight-based dosing may not be necessary for patients harboring genotype A since
highest response rates are found among those > 85kg. However, these findings need to be
confirmed in a larger study containing Peg-IFN α-2b therapy on a fixed dose and on a
weight-based dose regimen for further optimalization of Peg-IFN α-2b therapy.
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SUMMARY
Word-wide, infection with the hepatitis B virus (HBV) is a major health problem. Over 2
billion people have been exposed to HBV, and approximately 400 million are chronic carriers
of the virus. Chronic hepatitis B (CHB) infection may lead in term to liver cirrhosis, hepatic
decompensation and hepatocellular carcinoma (HCC), and is responsible for an estimated
1 million deaths annually.
The efficacy of the established treatment for CHB is limited. Treatment with conventional
interferon (IFN) is only effective in 20-35%. Lamivudine needs to be given long-term to
maintain response and leads to emergence of viral resistant strains. Several studies have
investigated different treatment options such as peginterferon, adefovir and entecavir. The
first randomized controlled trial in HBeAg-positive CHB with peginterferon - which had
proven to be more effective than conventional IFN in chronic hepatitis C patients -
demonstrated that a 52-week course of peginterferon alfa-2b leads to HBeAg seroconversion
in 36%,  ALT normalization in 35% and HBV DNA < 2.0 x 105 copies/mL in 32% of patients
at the end of post treatment follow-up. The addition of lamivudine did not enhance response
rates compared to peginterferon alfa-2b alone. The use of conventional IFN is not suited
for all patients due to the significant side effects and early treatment discontinuation that
may occur. Although the safety profile of peginterferon has been studied in chronic hepatitis
C, the side effects of peginterferon in CHB patients have not previously been investigated.
We assessed the safety of peginterferon treatment in 266 HBeAg-positive patients who
received peginterferon alfa-2b alone or in combination with lamivudine (chapter 2). The
most common side effects were similar to those reported for conventional IFN. Flu-like
symptoms, headache, fatigue, myalgia, local reaction at the injection, abdominal discomfort
and psychiatric symptoms were most frequently reported, but in general subsided during
the course of therapy. Hematologic abnormalities (leucopenia, neutropenia and
thrombocytopenia) were frequent but did not lead to serious infections or bleeding
complications. Neutropenia was the major cause for dose reductions of peginterferon,
whereas psychiatric symptoms (depression, psychosis) were the most important reasons
for early treatment discontinuation. Pre-existing cirrhosis at baseline was an important risk
factor for thrombocytopenia and (minor) bleeding complications.
During conventional IFN therapy and in the natural history of the disease, acute exacerbations
of CHB are a well-known phenomenon. Flares have been attributed to increased T cell
cytolytic activity and natural killer cell function and may herald HBeAg seroconversion.
Flares during treatment and follow-up of peginterferon alone or combined with lamivudine
occurred in 25% of patients (chapter 3). The frequency of all flares was comparable among
the HBV genotypes, but flares on-treatment were more frequent within genotype A than
genotype D. Flares during treatment were associated with response to therapy in contrast
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to those during post treatment follow-up. Close monitoring revealed  two different types
of flares; host-induced flares which were followed by a significant decrease in serum HBV
DNA levels, and virus-induced flares which were preceded by an increase in serum HBV
DNA. Virus-induced flares were detrimental for treatment outcome and occurred frequently
after treatment. These flares possibly reflect the exacerbations of HBV as described after
cessation of lamivudine and may be severe and life-threatening. In contrast, host-induced
flares were the strongest predictors for HBeAg loss, 58% of patients exhibiting a host-
induced flares had lost HBeAg at the end of follow-up. This further underlines that full
control and elimination of the virus is achieved by a vigorous host immune response rather
than by direct suppression of the virus.
In chapter 4 we investigated the frequency of HBsAg loss and the role of HBV genotype
after treatment. HBsAg seroclearance or HBsAg seroconversion is being regarded as the
ideal endpoint of therapy, since it is strongly associated with improved survival and reduction
of HCC. Spontaneous clearance is rare and treatment with nucleoside analogues seldom
leads to HBsAg seroconversion. After peginterferon therapy a total of 18 patients (7%)
were HBsAg negative at the end of follow up. The frequency of HBsAg clearance was
similar between the treatment groups. Among patients being HBsAg negative at the end of
follow-up all had normalized serum ALT levels and HBV DNA < 2.0 105 copies/mL. Sixty-
one percent was HBV DNA negative using in-house Taqman PCR (detection limit 400
copies/mL). In addition to HBeAg loss, HBV genotype was also strongly associated with
HBsAg loss. We found HBsAg seroclearance in 14% of patients harbouring genotype A
patients, 9% harbouring genotype B, 3% harbouring genotype C, and 2% harbouring genotype
D. Among HBeAg responders, 31%, 20%, 9% and 8% of patients lost serum HBsAg, respectively.
Although studies on new treatment options for CHB showed promising results, there is a
growing population of patients who previously failed to respond to the established therapies
with conventional IFN or lamivudine. As the efficacy of peginterferon therapy has not been
investigated in these difficult-to-treat population, we studied 76 patients who  previously
where non-responder to IFN and or lamivudine therapy (chapter 5). Treatment of
peginterferon alone or in combination with lamivudine lead to HBeAg loss in 35% of previous
non-responders to conventional IFN, 29% of non-responders to lamivudine and 18% of
non-responders to both therapies. ALT normalization was found in 24%, 41% and 14% of
previous non-responders, and HBV DNA levels < 400 copies/mL at the end of therapy was
found in 5%, 6%, and 0% of previous non-responders, respectively. Especially patients with
baseline ALT levels > 4 x upper limits of normal benefit from peginterferon therapy. Previous
dose and treatment duration were not associated with HBeAg loss. We performed additional
analyses in patients harbouring a YMDD mutation (chapter 6). This study revealed only
minor efficacy of peginterferon in patients carrying a mutation in the YMDD motif of the
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HBV. Only 2 patients (13%) converted to HBeAg negativity with ALT normalization and
HBV DNA levels < 2.0 x 105 copies/mL. This study suggests that the efficacy of peginterferon
in this specific population is limited, but larger studies are needed to draw definite conclusions.
Peginterferon in previous non-responders without the YMDD mutation seems beneficial.
In general, the response to IFN or peginterferon is durable in CHB patients, but relapse
after lamivudine therapy is frequently seen. The effect of peginterferon monotherapy or its
combination with lamivudine on relapse is still unknown (chapter 7). Relapse was more
often seen after cessation of peginterferon combined with lamivudine (39%) than after
peginterferon alone (13%). Multivariate analysis confirmed combination therapy as
independently predictive for relapse. Absence of anti-HBe at week 52 was an independent
predictor. Thus, HBeAg loss seems less suitable as sole endpoint, especially for those receiving
combination therapy. The development of anti-HBe in peginterferon monotherapy may be
less important, since the majority of patients treated in the monotherapy (7 of 10 patients)
did not relapse despite the absence of anti-HBe at the end of therapy. Further suppression
of HBV DNA levels could enhance sustained response, as mean HBV DNA levels were
lower in sustained responders compared to relapsers.
Increased body weight is a risk factor for non-response and relapse on peginterferon in
chronic hepatitis C. Studies with peginterferon alfa-2b which is normally administered on a
weight-based doses showed no relationship between increased weight and lower response
rates, while studies with peginterferon alfa-2a which is based on a fixed dose regimen
demonstrated decreased efficacy with higher body weight. We investigated the effect of
peginterferon alfa-2b in CHB using a fixed dose of 100 µg (chapter 8). For this study, 264
patients were categorized in 5 weight categories, ≤ 55 kg (n = 26), 55-65 kg (n = 59), 65-75
kg (n = 77), 75-85 kg (n = 58) or > 85 kg (n = 44). HBeAg response for the corresponding
weight groups was 46%, 42%, 31%, 24%, and 45% respectively. The vast majority of patients
> 85 kg consisted of patients with genotype A or D. Within genotype A, patients >85 kg
responded better than patients ≤ 85 kg, (83% vs. 39%), while the opposite was found for
genotype D, 8% vs. 29% for patients > 85kg and ≤ 85 kg. In contrast to genotype D patients,
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weight based dosing may not be needed in patients harbouring genotype A, but future
studies are needed to optimize treatment regimens for CHB.
CONCLUSIONS
1. Peginterferon alfa-2b is safe in HBeAg-positive chronic hepatitis B. Most side effects
occur during the first months of treatment, and all side effects are reversible after treatment
discontinuation.
2. Flares during peginterferon alfa-2b therapy could herald HBeAg response and should not
be treated with additional nucleoside analogue therapy. Host-induced flares strongly predict
response to therapy.
3. Peginterferon therapy is capable of enhancing HBsAg seroclearance or HBeAg
seroconversion. Especially patients with genotype A benefit from peginterferon alfa-2b
treatment.
4. Treatment of peginterferon alfa-2b alone or in combination with lamivudine is effective in
one-third of previous non-responders to conventional IFN or lamivudine. High baseline
ALT levels are the best predictors for response to therapy. Peginterferon alfa-2b therapy in
patients harbouring a YMDD mutation in the polymerase gene of HBV seems less effective.
5. HBeAg relapse occurs more often after treatment with peginterferon alfa-2b and
lamivudine than after peginterferon alfa-2b monotherapy. Absence of anti-HBe at the end
of treatment was found to be the strongest predictor of relapse, particularly in patients
treated with combination therapy.
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129Samenvatting en conclusies
SAMENVATTING
Infectie met het hepatitis B virus (HBV) is wereldwijd een groot gezondheidsprobleem.
Meer dan 2 miljard mensen zijn in aanraking geweest met HBV en ongeveer 400 miljoen
zijn chronisch drager van het virus. Chronische hepatitis B (CHB) infectie kan leiden tot
levercirrose, hepatische decompensatie en hepatocellulair carcinoom (HCC). Tevens is CHB
verantwoordelijk voor een geschat aantal van 1 miljoen doden per jaar.
De effectiviteit van de gevestigde behandelingen van CHB is beperkt. Behandeling met
standaard interferon (IFN) is slechts effectief in 20-35%. Lamivudine moet lang gegeven
worden om de respons te handhaven en leidt tot het ontstaan van therapieresistentie
stammen. Verscheidene studies hebben verschillende behandelingsmogelijkheden onderzocht
zoals peginterferon, adefovir of entecavir. De eerste gerandomiseerde trial in HBeAg positieve
CHB patiënten met peginterferon, dat bewezen effectiever is dan standaard IFN in chronische
hepatitis C, demonstreerde dat een 52 weken durende behandeling met peginterferon alfa-
2b leidde tot HBeAg seroconversie in 36%, normalisatie van ALT waarden in 35% en HBV
DNA waarden < 2.0 x 105 kopieen/mL in 32% van de patiënten aan het einde van de
follow-up. De toevoeging van lamivudine verbeterde de respons percentages niet in
vergelijking met alleen peginterferon alfa-2b. Standaard IFN behandeling is niet geschikt
voor alle patiënten aangezien de behandeling gepaard gaat met medisch relevantie
bijwerkingen, waarbij vervroegd stoppen met de behandeling genoodzaakt kan zijn. Alhoewel
het bijwerkingenprofiel van peginterferon in chronische hepatitis C bestudeerd is, zijn de
bijwerkingen van peginterferon in CHB nog niet onderzocht. Wij stelden de veiligheid vast
van peginterferon alfa-2b alleen of in combinatie met lamivudine in 300 HBeAg positieve
patiënten (hoofdstuk 2). De meest voorkomende bijwerkingen waren vergelijkbaar met die
van standaard IFN. Griepverschijnselen, hoofdpijn, vermoeidheid, spierpijn, lokale reactie op
de injectieplaats, buikklachten en psychiatrische symptomen waren meest frequent, maar
verdwenen in het algemeen in de loop van de behandeling. Hematologische veranderingen
(leukopenie, neutropenie en thrombocytopenie) werden vaak gezien, maar leidden niet tot
ernstige infecties of bloedingcomplicaties. Neutropenie was de meest voorkomende oorzaak
voor dosisreducties, psychiatrische bijwerkingen (depressie, psychose)  waren de belangrijkste
oorzaken van vervroeg stoppen met de behandeling. Reeds bestaande cirrose aan het begin
van de therapie bleek de belangrijkste factor voor thrombocytopenie en (kleine)
bloedingcomplicaties.
Tijdens standaard IFN behandeling en in het natuurlijk beloop van de ziekte, zijn acute
opvlammingen van CHB een bekend verschijnsel. Deze 'flares' worden toegeschreven aan
verhoogde T cel activiteit en de 'natural killer' cel functie en kunnen een voorbode zijn van
HBeAg seroconversie. Flares tijdens therapie en follow-up van peginterferon alleen of
gecombineerd met lamivudine gebeurde in 25% van de patiënten (hoofdstuk 3). De frequentie
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van alle flares was vergelijkbaar tussen de verschillende HBV genotypen, maar flares tijdens
therapie werden vaker gezien in genotype A dan in genotype D patiënten. Flares tijdens
therapie waren geassocieerd met respons op behandeling, dit in tegenstelling tot flares
optredend na behandeling. Nauwkeurige registratie onthulde 2 verschillende patronen flares;
'host-geïnduceerde' flares werden gevolgd door een sterke daling van HBV DNA waarden.
'Virus-geïnduceerde' flares werden voorafgegaan door een sterke stijging van de HBV DNA
waarden. Virus-geïnduceerde waren nadelig voor de behandelingsuitkomst en traden met
name op na therapie. Deze flares reflecteren waarschijnlijk de exacerbaties van CHB zoals
beschreven na het stoppen van lamivudine en kunnen ernstig en levensbedreigend zijn. In
tegenstelling tot virus-geïinduceerde waren host-geïnduceerde flares sterk predictief voor
HBeAg verlies, 58% van de patiënten met een host-geïnduceerde flare was HBeAg negatief
aan het einde van de follow-up. Dit onderstreept te meer dat volledige controle en eliminatie
van het virus wordt bereikt door een sterke immuunrespons in plaats van enkel onderdrukkin
van het virus.
In hoofdstuk 4 onderzochten we de frequentie van HBsAg verlies en de rol van het HBV
genotype op de behandeling. HBsAg klaring of HBsAg seroconversie wordt beschouwd als
het ideale doel van de behandeling, aangezien dit sterk geassocieerd is met verbeterde
overleving en reductie van HCC. Spontane klaring van HBsAg is zeldzaam en behandeling
met nucleoside analogen leidt eveneens zelden tot HBsAg seroconversie. In totaal waren
18 patiënten (7%) HBsAg negatief na behandeling met peginterferon aan het einde van de
follow-up met geen verschil tussen de beide behandelingsgroepen. Onder HBsAg negatieve
patiënten aan het einde van de follow-up had iedereen genormaliseerde ALT waarden en
HBV DNA waarden < 2.0 x 105 kopieën/mL. Eenenzestig procent was HBV DNA negatief
gemeten met de 'in-house Taqman PCR' (detectie limiet 400 kopieën/mL). Evenals bij HBeAg
verlies was HBV genotype sterk geassocieerd met HBsAg verlies. Wij vonden HBsAg klaring
in 14% van de genotype A, 9% van de genotype B, 3% van de genotype C en in 2% van de
genotype D patiënten. Onder HBeAg negatieve patiënten werden respectievelijk 31%, 20%,
9% en 8% HBsAg negatief aan het einde van de follow-up.
Hoewe recente studies met nieuwe therapieopties veelbelovende resultaten laten zien,
groeit de populatie van patiënten die eerder niet reageerden op standard IFN of lamivudine
therapie. Tot op heden is de effectiviteit van peginterferon in deze group moeilijk te
behandelen patiënten onbekend. Wij onderzochten 76 patiënten die eerder non-responder
waren op standaard IFN en-/of lamivudine behandeling (hoofdstuk 5). Behandeling met
peginterferon al dan niet gecombineerd met lamivudine, leidde in 35% van de eerdere non-
responders op standaard IFN, 29% van de non-responders op lamivudine en 18% van de
non-responders op zowel IFN als lamivudine tot HBeAg respons. Respectivelijk werd
normalisatie van serum ALT waarden gezien in 24%, 41% en 14% van de non-responders.
Aan het einde van de therapie had 5% van de non-responderes op IFN, 6% van de non-
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responders op lamivudine en 0% van de non-responders op beide therapieën HBV DNA
waarden < 400 kopieën/mL. Met name patiënten die aan het begin van de behandeling ALT
waarden > 4 x de normaal waarde hadden reageerden goed op de peginterferon behandeling.
Duur en dosis van de eerdere behandeling beinvloedde de uitkomst van therapie niet.
Een uitgebreidere analyse van patiënten met een YMDD mutatie wordt in hoofdstuk  6
beschreven. Deze studie liet een lage effectiviteit van peginterferon zien in patiënten die
drager zijn van een YMDD mutatie van het virus. Slechts 2 patiënten (13%) converteerde
naar HBeAg negativiteit gecombineerd met ALT normalisatie en HBV DNA < 2.0 x 105
kopieen/mL aan het einde van de follow-up. Deze resultaten suggereren dat de effectiviteit
van peginterferon beperkt is in deze populatie. Echter, grotere studies zijn nodig om defintieve
conclusies te kunnen trekken. Peginterferon in eerdere non-responders zonder YMDD
mutatie lijkt gunstig effectief.
In het algemeen is de respons op standaard IFN of peginterferon behandeling in CHB
patiënten duurzaam, maar terugkeer van de ziekte (relaps) na het stoppen van lamivudine
wordt frequent gezien. Het effect van peginterferon al dan niet gecombineerd met lamivudine
op relaps is nog steeds onbekend (hoofdstuk 7). Relaps gebeurde vaker na het stoppen van
de combinatie therapie van peginterferon met lamivudine (39%) dan na het stoppen van
peginterferon monotherapie. Multivariate analyse bevestigde combinatietherapie als
onafhankelijk predictieve factor. Afwezigheid van anti-HBe op week 52 was eveneens een
onafhankelijk factor. HBeAg negativiteit alleen lijkt derhalve minder geschikt als eindpunt
van behandeling, vooral voor patiënten behandeld met combinatietherapie. De aanwezigheid
van anti-HBe bij peginterferon monotherapie lijkt minder belangrijk aangezien de
meerderheid van de patiënten (7 van de 10) geen relaps kreeg ondanks de afwezigheid van
anti-HBe. Verder suppressie van HBV DNA waarden zou de effectiviteit kunnen vergroten,
vanwege de lagere gemiddelde HBV DNA waarden in de blijvende responders vergeleken
met diegene met een relapse.
Hoger lichaamsgewicht is een risicofactor voor het niet reageren op peginterferon in
chronische hepatitis C patiënten. Studies met peginterferon alfa-2b, dat gedoseerd wordt
op basis van lichaamsgewicht, liet geen relatie zien tussen hoger lichaamgewicht en respons,
terwijl studie met peginterferon alfa-2a, dat een vaste dosis heeft, vermindere effectiviteit
liet zien in zwaardere patiënten. Wij onderzochten het effect van een vaste dosis peginterferon
alfa-2b van 100 µg in CHB (hoodstuk 8). Voor deze studie werden 264 patiënten in 5
gewichtscategorieën ingedeeld,  ≤ 55 kg (n = 26), 55-65 kg (n = 59), 65-75 kg (n = 77), 75-
85 kg (n = 58) or > 85 kg (n = 44). HBeAg response voor de corresponderende groepen
was 46%, 42%, 31%, 24%, and 45%. De grote meerderheid van patiënten > 85 kg bestond uit
genotype A of D. Onder de genotype A groep, reageerden patiënten > 85 kg beter dan die
≤ 85 kg (83% vs. 39%), terwijl het tegenovergestelde voor genotype D patiënten werd
gevonden, 8% vs. 29% voor patiënten > 85 kg en ≤ 85 kg. In tegenstelling tot genotype D
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patiënten is dosering van peginterferon alfa-2b wellicht niet nodig voor genotype A, maar
toekomstige studies moeten uitsluitsel bieden.
CONCLUSIES
1.  Peginterferon alfa-2b is veilig in HBeAg-positieve chronische hepatitis B. De meeste
bijwerkingen worden gezien gedurende de eerste maanden van behandeling en alle
bijwerkingen zijn reversibel na stoppen van therapie.
2.  Flares tijdens peginterferon alfa-2b therapie kunnen een voorbode zijn van HBeAg
respons en dienen niet met additionele nucleoside analogen behandelt te worden. Host-
geïnduceerde flares hebben eens sterk voorspellende waarde op respons.
3.  Peginterferon is in staat tot HBsAg klaring en HBsAg seroconversie te vergroten. Met
name patiënten drager van het genotype A profiteren het meest van peginterferon alfa-2b
therapie.
4.  Behandeling van peginterferon alfa-2b al dan niet in combinatie met lamivudine is effectief
in eenderde van eerdere non-responders op standard IFN of lamivudine. Hoge
aanvangswaarden van ALT zijn de beste voorspellers voor response op therapie. De
effectiviteit van peginterferon alfa-2b in patiënten die een YMDD mutatie dragen lijkt
afgenomen.
5.  HBeAg relaps gebeurt vaker na het stoppen van de combinatie van peginterferon alfa-2b
met lamivudine dan na peginterferon alfa-2b alleen. Afwezigheid van anti-HBe aan het einde
van de therapie was de sterkste voorspeller op relaps, vooral in patiënten behandelt in de
combinatietherapie.
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135Appendix
APPENDIX
The HBV 99-01 Study Group includes the following investigators:
The Netherlands: H.G.M. Niesters, P.E. Zondervan, M. van Zonneveld, R.A. de Man, S.W.
Schalm, H.J. Flink, H.L.A. Janssen, M.J. ter Borg (University Medical Center Rotterdam),
B.C.M. Vroom (University Medical Center Utrecht) C.M.J. van Nieuwkerk (VU University
Medical Center Amsterdam), R.A. de Vries (Rijnstate Hospital Arnhem), J. Jansen, J.Drenth,
S.J.van den Hazel (University Medical Centre Radboud Nijmegen), J.W. den Ouden-Muller
(St. Franciscus Hospital Rotterdam), A.C. Tan (Canisius Wilhelmina Hospital Nijmegen);
Belgium: D.M. Adler (Hopital Erasme Brussels), P. Michielsen (University Hospital Antwerp),
H. van Vlierberghe (University Hospital Gent), F. Nevens (University Hospital Leuven), J.
Delwaide (Centre Hospitalier Universitaire Liège), J. Henrion (Hopital de Jolimont, Haine
St. Paul); Germany: S. Zeuzem (Saarland University Hospital, Homburg/Saar), G.Gerken, S
Bein, U. Treichel (University Hospital Essen), J. Trojan (J.W. Goethe Universität Frankfurt),
M.P. Manns, J. Hadem (Medizinische Hochschule Hannover), C. Niederau (St. Jozef Hospital
Oberhausen); Denmark: M.R. Buhl, I.M. Hansen (Skejby Hospital, Arhus), K. Krogsgaard
(Copenhagen University Hospital Hvidovre); Poland: C. Simon (Medical University, Wroclaw),
J. Cianciara, J. Jablonska, J Kozlowska (Medical Academy of Warsaw), D. Prokopowicz, R.
Flisiak (Medical Academy of Bialystok), T. Mach (Collegium Medicum UJ Kraków); Spain: M.
Buti, A. Valdes, R Esteban (Hospital Valle Hebron, Barcelona), M. Rodriguez, M. Garcia Espiga
(Hospital Central de Asturias, Oviedo); Italy: A. Andriulli, G. Stornaiulo, G.B. Gaeta (Ospe.
Gesù e Maria, Napoli), G. Montalto, F. D'Antona (Università di Palermo); Greece: G.E. Kitis,
P. Xiarchos Panagiotis (George Papanikolaou General Regional Hospital,Thessaloniki), N.C.
Tassopoulos (West Attica Hospital Athens);  Turkey:  U.S. Akarca, G. Ersöz (Ege University
Faculty of Medicine Izmir), S. Karayalcin, C. Yurdayin, H. Bozkaya (Medical School Cebeci
Kampusu Ankara), H. Simsek, Y. Balaban (Hacettepe University Faculty of Medicine Ankara),
H. Senturk, F. Tabak (Istanbul University Cerrahpasa Medical School, Istanbul), Y. Cakaloglu
(Medical Faculty, University of Istanbul, Istanbul) ; Israel: Y. Lurie (Sauraski Medical Center
Tel-Aviv); Canada: J. Heathcote (Toronto Western Hospital, Toronto); S.V. Feinman (Mount
Sinai Hospital Toronto); S. Greenbloom (General Hospital Etobicoke); Indonesia: D.A. Sulaiman
(Ciptomangunkusomo Hospital Jakarta); Singapore: R. Guan (Mount Elizabeth Medical Center
Singapore); Malaysia: I. Merican (Institute for Medical Research Kuala Lumpur); China: T.M.K.
So (Princess Margaret Hospital, Hong Kong).
136
C
ha
pt
er
 9
137Dankwoord
Last but not least… het dankwoord. Met de stellingen waarschijnlijk een van de meest
gelezen stukken van ieder proefschrift. En zoals bij iedere totstandkoming van een proefschrift,
zijn er veel mensen bij betrokken geweest, die ook ik graag wil bedanken.
Allereerst wil ik Harry Janssen bedanken voor de uitstekende samenwerking de afgelopen
jaren. Met jou als supervisor tijdens mijn afstudeeronderzoek, leerde ik de MDL afdeling
kennen en maakte ik voor het eerst echt kennis met wetenschappelijk onderzoek. Jouw
drive werkte aanstekelijk. Bedankt voor de mogelijkheid om dit onderzoek voort te zetten
in een promotieonderzoek. Waar ik in het begin nog twijfelde om niet eerst mijn artsexamen
af te ronden, was ik er snel zeker van dat ik de juiste keuze gemaakt had. Je immer kritische
blik als aanvankelijk co-promotor en later als promoter en de tijd die je nam voor de
begeleiding hebben mede geleid tot het goed gevolg van dit proefschrift!
Ernst Kuipers wil ik hierbij bedanken voor de mogelijkheid om als wetenschappelijk
onderzoeker op de afdeling Maag-, Darm-, en Leverziekten te werken. Ik heb tweeënhalf
jaar met veel plezier op deze afdeling gewerkt!
De promotiecommissie wil ik graag bedanken voor het doorlezen van het proefschrift.
Hierbij wil ik graag Solko Schalm en Rob de Man bij naam noemen, die ik ook wil bedanken
voor het reviewen van de manuscripten van de afgelopen jaren.
Een manuscript schrijven gaat niet zonder de nodige statistische analyses. Gelukkig spreekt
één iemand SPSS vloeiend. Bettina, hartelijk dank voor al je hulp ondanks je overvolle
agenda!
Zoals gezegd was mijn eerste kennismaking de MDL, was in het kader van mijn afstuderen.
Dit eerste half jaar dat ik op de afdeling zat, was ik gehuisvest op kamer CA 326. Voor
diegene die niet bekend zijn met de MDL, hier zitten Margriet en Marion. Dat ik hier een
erg leerzame én gezellige tijd heb gehad spreekt voor zich! Margriet en Marion, heel erg
bedankt hiervoor en natuurlijk voor alle regeldingen, zoals het submitten van manuscripten
en abstracts tijdens mijn promotieonderzoek!
De laatste twee jaar van mijn onderzoek zat ik in het Mondriaangebouw, beter bekend als
de dakpoli. Bart, Els en later ook Geert, jullie waren uitstekende kamergenoten. Samen
hebben we op de kamer veel onderzoeksperikelen en tropische temperaturen moeten
doorstaan. Bedankt voor alles de afgelopen twee jaar!
Een van mijn bezigheden de afgelopen twee jaar was de “Long-term Follow-up” studie.
Zonder de hulp van het "HBV team" was dit een onmogelijke taak geworden. Hierbij wil de
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ik de HBV mannen Martijn, Wim en Erik bedanken voor het includeren van de patiënten in
de studie en voor al jullie andere hulp in welke vorm dan ook.
Hanneke, Renate, Angela en Martine wil bedanken voor de verwerking van alle samples en
alle andere laboratische onderdelen.
Bij een dergelijke studie spelen logistiek en dataverwerking ook een erg belangrijke rol.
Elke, Wanda, Claudia, Eva, bedankt voor alle adviezen en goede hulp! In een adem door wil
ik hierbij de researchverpleegkundigen Cokki, Heleen en Anneke noemen. Bedankt voor
jullie ervaring en het verzamelen van de bloedsamples (het prikken van de patiënten).
De goede sfeer en collegialiteit op de afdeling maakten dat de tweeënhalf jaar dat ik werkzaam
was op de MDL voorbij zijn gevlogen! Ik wil alle MDL collega’s bedanken voor deze tijd (de
vrijdagmiddagborrel zal ik missen). Veel succes met jullie promoties!
Mijn ouders wil ik bedanken voor hun steun en vrijheid die ze me al 27 jaar lang hebben
gegeven.
Mijn paranimfen Jelle en Robartus wil ik bedanken voor hun hulp en brainstormsessies die
we de laatste maanden gehouden hebben. Al van jongs af aan bevriend in Veendam en nu alle
drie wonend in de randstad. Wie had gedacht dat jullie ooit als paranimfen naast mij zouden
staan!?  Vrienden voor het leven.
Lieve Sanne, bedankt voor je geduld als ik weer eens op zondagmiddag achter de PC kroop.
Je hulp hierbij was fantastisch. Met het afsluiten van dit proefschrift krijgen we zeker meer
tijd voor leuke dingen! Bedankt voor je onvoorwaardelijke steun.
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CURRICULUM VITAE
De auteur van dit proefschrift werd geboren op 24 december 1978 te Veendam. Na het
behalen van zijn V.W.O. diploma aan het "O.S.G. Winkler Prins" in 1997, studeerde hij
Technische Bedrijskunde aan de Rijksuniversiteit Groningen. In 1998 werd hij ingeloot voor
de studie Geneeskunde aan de Erasmus Universiteit Rotterdam. Al vroeg in deze periode
ontstond de interesse in maag-, darm- en leverziekten, wat resulteerde in een
afstudeeronderzoek naar de bijwerkingen van peginterferon bij chronische hepatitis B.
Aansluitend werkte hij tot december 2005 als wetenschappelijk onderzoeker op de afdeling
Maag-, Darm- en Leverziekten van het Erasmus MC. Onder leiding van zijn co-promotor
en tevens promotor prof. dr. H.L.A Janssen vervolgde hij zijn onderzoek naar de effecten
van peginterferon behandeling bij chronische hepatitis B patiënten. In februari 2006 startte
hij met zijn co-schappen om de opleiding tot basisarts te voltooien. Tijdens zijn
promotieonderzoek volleybalde hij onder andere bij eredivisionist "Rijnmond Volleybal". Hij
woont samen met Sanne Ros.
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143Abbreviations
LIST OF ABBREVIATIONS
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
BMI body mass index
cccDNA covalently closed circular DNA
CHB chronic hepatitis B
CI confidence interval
DNA Deoxyribonucleic Acid
HCC hepatocellular carcinoma
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HDV hepatitis D virus
HIV human immunodeficiency virus
IFN interferon
mL mililiter
NA nucleoside analogue
NR non-responder
ORF open reading frame
PCR polymerase chain reaction
PEG polyethylene glycol
Peg-IFN pegylated interferon
RR relative risk
RNA ribonucleic acid
SAE serious adverse event
SD standard deviation
SSRi specific serotonin reuptake inhibitor
U units
ULN upper limit of normal
WBC white blood cell count
WHO World Health Organisation
YMDD thyrosine methionine aspartate aspartate
